Compounds, process for obtaining the compounds, pharmaceutical compositions, pharmaceutical combinations, medicaments, uses and methods of treatment

A novel dual-action compound with muscarinic M3 and histamine H1 receptor antagonist activity addresses gastroenterology and respiratory diseases with long-lasting relief and reduced side effects, enhancing treatment efficacy and compliance.

WO2026232206A1PCT designated stage Publication Date: 2026-11-12ACHE LAB FARM
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/BR2025/050167
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2025-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current treatments for gastroenterology and respiratory diseases, such as inflammatory bowel syndrome, food allergies, and chronic obstructive pulmonary disease, often require multiple daily doses and fail to provide rapid and sustained relief from symptoms, with potential side effects and limited efficacy.

Method used

Development of a novel compound with dual muscarinic M3 and histamine H1 receptor antagonist activity, offering long-acting relief by combining antihistaminic and muscarinic receptor actions in a single molecule for intranasal, inhaled, and oral administration.

Benefits of technology

The compound provides comprehensive and sustained symptom relief with reduced side effects, improving patient compliance and quality of life by addressing multiple disease facets simultaneously.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000008_0001
    Figure IMGF000008_0001
  • Figure IMGF000009_0001
    Figure IMGF000009_0001
  • Figure IMGF000009_0002
    Figure IMGF000009_0002
Patent Text Reader

Abstract

The present invention relates to novel pharmaceutical compounds with long- acting muscarinic receptor antagonism or dual acting compounds with combined properties of muscarinic receptor antagonist and antihistaminic activity for the treatment of gastroenterology and respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD) and rhinitis. The present invention involves the synergistic action of two classes of drugs in a single molecule for improved efficacy, with rapid and sustained relief of symptoms, improved patient compliance and reduction of the risk of side effects.
Need to check novelty before this filing date? Find Prior Art

Description

DescriptionTitle of Invention: COMPOUNDS, PROCESS FOR OBTAINING THE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, PHARMACEUTICAL COMBINATIONS, MEDICAMENTS, USES AND METHODS OF TREATMENT Field of the invention

[0001] The present invention relates to novel pharmaceutical compounds with long dual acting activities with combined properties of both muscarinic receptor antagonist and antihistaminic. These unique compounds offer a promising solution with long duration of action and once daily potential for the intranasal, inhaled and oral routes for the treatment of gastroenterology and respiratory diseases, including but not limited to inflammatory bowel syndrome (IBS), food allergy, food intolerance disorders, histamine intolerance, functional dyspepsia, eosinophilic esophagitis, gastroesophageal reflux disease (GERD), asthma, chronic obstructive pulmonary disease (COPD) and rhinitis, by addressing unmet needs of the condition simultaneously, resulting in rapid and sustained relief of symptoms, improved patient compliance and reduction of the risk of side effects. The invention also covers a process to obtain said compounds, a pharmaceutical composition and a medicament comprising such compounds, pharmaceutical combinations, the use of at least one compound and a method of treatment.

[0002] The present invention recognizes the potential for a pharmaceutical composition that combines the benefits of antihistaminic agents and muscarinic receptor antagonists to provide comprehensive relief for gastrointestinal, allergic and respiratory diseases symptoms. By incorporating both mechanisms of action within a single compound, the composition synergistically alleviates several symptoms like discomfort, allergic and immunological reactions, motility, secretion, itching, swelling, redness, and congestion, providing superior therapeutic outcomes compared to separate administrations of antihistamines and muscarinic receptor antagonists. Moreover, a single chemical entity offers severaladvantages compared to a fixed-dose combination, such as synchronized action, extended tissue residency time and easier formulation requirements Background of the Invention

[0003] HISTAMINE RECEPTORS

[0004] Histamine is a biogenic amine involved in numerous physiological reactions and is synthesized and released by several human cells, for example, mast cells, basophils, platelets, lymphocytes, enterochromaffin-like cells of the gastric mucosa and histaminergic neurons.

[0005] Histamine exerts its biologic effects through four types of receptors: H1 , H2, H3 and H4 receptors. Said receptors are expressed throughout the human body, mainly, H1 and H2 receptors are the most widely distributed in the body, while the H3 receptors are found mainly in the central nervous system and the H4 receptors on the bone marrow and peripheral hematopoietic cells, eosinophils, neutrophils, DC, T cells, basophils and mast cells.

[0006] H1 receptors are found in the CNS, smooth muscle, sensory nerves, heart, adrenal medulla, and immune cells and are responsible for some of the typical allergy reactions, including pruritus, sneezing, pain, vasodilation vascular permeability, hypotension, flushing, tachycardia, bronchoconstriction, rhinorrhea and contraction of the smooth muscle in the respiratory and gastrointestinal tract.

[0007] H2 receptors can be found in the heart, smooth muscle cells and gastric mucosal cells. These receptors can mediate hydrochloric acid secretion, vascular permeability, hypotension, tachycardia and bronchoconstriction.

[0008] H3 receptors can modulate the release of histamine, noradrenaline, dopamine, serotonin, acetylcholine, and gamma amino-butyric acid in the CNS and mediate neurogenic sympathetic vasoconstriction in the nasal mucosa.

[0009] H4 receptors are involved in differentiation of myeloblasts and promyeloblasts and chemotaxis and have an important role in inflammatory disorders and autoimmune diseases.

[0010] Antihistamines are mainly divided into two classes: H1 and H2 antihistamines, wherein H1 antihistamines are commonly used to manage allergy symptoms, such as urticaria, allergic rhinitis, and hay fever; through their action being (majorly) as inverse agonists at the H1 receptors.

[0011] H1 antihistamines can be further classified in first generation and second generation. First generation antihistamines are non-selective in binding to the H1 receptor and can easily penetrate the blood-brain barrier into the central nervous system. Meanwhile, second generation antihistamines have low lipid solubility and high molecular weight, thus not easily penetrating the blood-brain barrier and selectively binding to peripheral H1 receptors. Due to this, the second generation H1 antihistamines do not present the side effects common in the first generation antihistamines like sedation and cognitive impairing performance. Examples of H1 antihistamines include cetirizine, diphenhydramine, chlorpheniramine and hydroxyzine.

[0012] H2 antihistamines are used for treating gastrointestinal conditions through their action as inverse agonists of the H2 receptors in the parietal cells of the stomach, decreasing the production of gastric acid. Thus, H2 antihistamines can be used to treat peptic ulcers, gastroesophageal reflux disease (GERD), and dyspepsia. Examples of H2 antihistamines are: cimetidine, famotidine, ranitidine and roxatidine.

[0013] Other HR antagonists include H3 antihistamines used for treatment of neurodegenerative disorders and H4 antihistamines, which are being investigated in their actions for treating allergy and inflammation conditions.

[0014] MUSCARINIC RECEPTORS

[0015] Muscarinic receptors play a significant role in the pathophysiology of several diseases. These receptors are a type of cholinergic receptor found in various tissues, including the nasal mucosa. They are primarily activated by the neurotransmitter acetylcholine and play a role in regulating various physiological processes, including the secretion of mucus and the contraction of smooth muscle in the airways.

[0016] Mucus Secretion: Muscarinic receptors, when activated, stimulate the secretion of mucus from goblet cells in the nasal mucosa. This increasedmucus production contributes to nasal congestion and a runny nose, which are common symptoms of rhinitis.

[0017] Smooth Muscle Contraction: Muscarinic receptors can also lead to the contraction of smooth muscles in the airways and blood vessels. In the nasal passages, this can result in nasal congestion and decreased airflow.

[0018] Muscarinic receptor antagonists (anticholinergics) target the parasympathetic nervous system and reduce the secretion of nasal fluids, potentially addressing the issue of excessive nasal discharge. However, they do not specifically target histamine-mediated responses. Ipratropium bromide is the only muscarinic receptor antagonist approved as a nasal spray for the treatment of rhinorrhea (runny nose) associated with allergic and non-allergic rhinitis. While it can be effective in relieving certain nasal symptoms, ipratropium nasal spray has some disadvantages and potential side effects, including:

[0019] - Limited Efficacy for Certain Symptoms: Ipratropium nasal spray is primarily effective in reducing rhinorrhea (nasal discharge) by inhibiting nasal secretions. However, it may not be as effective in relieving other symptoms of rhinitis, such as nasal congestion and sneezing. Patients with these additional symptoms may require other medications in addition to ipratropium.

[0020] - Delayed Onset of Action: Ipratropium nasal spray may not provide rapid relief of symptoms. It may take some time for the medication to become effective, which can be frustrating for individuals seeking immediate relief from nasal congestion or runny nose.

[0021] - Local Irritation: Some individuals may experience mild irritation or dryness of the nasal mucosa as a side effect of ipratropium nasal spray. This can lead to discomfort, especially with prolonged use.

[0022] - Taste Alterations: Occasionally, ipratropium may cause a bitter taste or unusual taste sensations in the mouth or throat, which can be unpleasant for patients.

[0023] - Limited Duration of Action: The duration of action of ipratropium nasal spray may be relatively short-lived, typically lasting for a few hours. Thisnecessitates frequent dosing, up to four times a day, for sustained symptom relief.

[0024] Thus, there remains an unmet need for long-acting once-a-day nasal sprays in the management of rhinitis, which can provide better:

[0025] Patient Compliance: One of the challenges in treating rhinitis is patient compliance with medication regimens. Many existing nasal sprays require multiple daily doses, which can be inconvenient for patients and may lead to poor adherence to treatment plans. A long-acting once-a-day nasal spray can simplify the treatment regimen and improve patient compliance.

[0026] Symptom Control: Rhinitis symptoms can be bothersome and impact a patient's quality of life. Long-acting nasal sprays can provide sustained relief from symptoms throughout the day, reducing the need for frequent re-dosing and ensuring consistent symptom control.

[0027] Reduced Side Effects: Long-acting formulations may allow for the use of lower doses of medications, potentially reducing the risk of side effects associated with nasal sprays, such as dryness or irritation of the nasal mucosa.

[0028] Improved Management: Chronic rhinitis, including allergic and non- allergic forms, often require long-term management. Long-acting nasal sprays can be particularly beneficial for individuals with persistent symptoms, allowing for effective control of their condition with fewer daily applications.

[0029] Ipratropium (M3R antagonist) is a safe and effective medication for treating nasal symptoms, reducing the severity and duration of rhinorrhea in allergic and non-allergic rhinitis. It is the only intranasal anticholinergic available, and it needs to be used three or four times daily - unmet need for a once daily treatment with such mechanism of action (M3 receptor antagonism). Antagonism of M3 receptors also Alleviates Type 2 Inflammation in Allergic Rhinitis.

[0030] Combination of M3 and H1 receptor antagonism potentiates the treatment of rhinorrhea and improves quality of life in rhinitis patients.

[0031] In recent years, pharmaceutical companies have been developing and marketing long-acting twice or once-a-day nasal sprays that target various aspects of rhinitis, including muscarinic receptors. These medications aim to provide more convenient and effective options for individuals suffering from rhinitis and rhinorrhea.

[0032] A search in patent and non-patent literature didn’t reveal any compound presenting pharmacological activity both in muscarinic receptor and histaminic receptors for treating respiratory and / or gastroenterology diseases according to the Markush compounds claimed in the present invention.

[0033] W002072093A2 (Schering Corp) discloses compounds with dual histamine H3 receptor antagonist I M2 muscarinic antagonist for the treatment of cognition deficit disorders. The disclosed compounds of W002072093A2 and its uses are different from the compounds of the present invention as described herein, thus it does not anticipate nor motivate a skilled person to arrive in the present invention.

[0034] Therefore, there remains a need for further treatment options that offer rapid and sustained relief from gastrointestinal and / or respiratory conditions.Summary of the Invention

[0035] The novel compound of the present invention involves long-acting muscarinic receptor activity and dual-acting compounds combining, in the same molecule, the properties of muscarinic M3 and histamine H1 receptor antagonists. These long-acting and / or dual-action compounds provide a comprehensive approach to treating gastroenterology and respiratory diseases, including but not limited to inflammatory bowel syndrome (IBS), food allergy, food intolerance disorders, histamine intolerance, functional dyspepsia, eosinophilic esophagitis, gastroesophageal reflux disease (GERD) asthma, chronic obstructive pulmonary disease (COPD) and rhinitis.

[0036] Developing a single molecule with both antihistaminic and muscarinic receptor activity offers a comprehensive and synergistic approach to symptom relief. The rationale for combining antihistaminic and muscarinic receptor activity lies in the complementary mechanisms of action.Antihistamines block the effects of histamine, which leads to symptoms like itching and sneezing, while muscarinic antagonists block the effects of acetylcholine, reducing symptoms like nasal congestion and excessive mucus production. Together, these actions can provide a more holistic approach to symptom relief.

[0037] Rhinitis symptoms are often driven by two primary mechanisms:histamine release (mediated by histamine receptors) and cholinergic stimulation (mediated by muscarinic receptors). Developing a single molecule that combines antihistaminic and muscarinic receptor activity for the treatment of rhinitis can offer several advantages, primarily by addressing multiple facets of the disease simultaneously and generating comprehensive symptom relief of symptoms like congestion, sneezing, itching, and excessive mucus production.

[0038] Moreover, a gastrointestinal disorder that could benefit from the use of the compounds of the invention is, for example, intestinal bowel syndrome (IBS), considering that acetylcholine is involved in gastrointestinal motility, the use of a muscarinic antagonist may inhibit this motility, providing relief of abdominal pain and diarrhea symptoms. In combination with the muscarinic antagonist, the use of an antihistamine can also provides abdominal pain relief in IBS patients, as there are studies showing that mast cells are increased in their intestines, thus secreting a higher amount of histamine in the colonic nerves correlated with seventy and frequency of abdominal pain in IBS patients.

[0039] Therefore, the present invention solves the technical problems through the provision of a novel compound of Formula I or its pharmaceutically acceptable salts:

[0040] [Chem. 1] - Formula Iwherein,X is selected from nitrogen or C-H;n = is an integer number selected from 0, 1 , 2, 3 or 4;m = is an integer number selected from 0, 1 or 2;R is a racemate selected from C-alkyl linear or branched chain (C1-C20), 0- or A / / - / -alkyl linear or branched chain (C1-C20);Y is selected from nitrogen or C-H;Z is selected from CH2, C-alkyl linear or branched chain (C1-C20), / V-alkyl linear or branched chain (C1-C20), oxygen, sulfur, sulfoxide or sulfone.M is selected from CH2, nitrogen, oxygen, sulfur, sulfoxide or sulfone;L is selected from CH2, nitrogen, oxygen or sulfur;A is absent or selected from hydrogen, alkyl linear or branched chain (C1-C20);His is a moiety selected from:

[0041] The present invention also provides a process to obtain the compound of Formula I, defined in the first aspect, comprising the steps of:a) reacting compounds of formulas II and III under basic condition to obtain a product comprising the formula IV:Formula II Formula III Formula IVb) if Z in Formula IV is sulfur, optionally react compound of formula IV with an oxidant prior to step c);c) react a compound of formula IV under reductant conditions, followed byprotection reaction with the remaining alcohol residue, that form a product comprising the formula V:d) react the compounds of formula V and VI under mild conditions, followed by deprotection group under acidic conditions to form a compound of Formula VII:Formula VIIe) react the compounds of formula VII and VIII under reductive amination conditions to form a compound of Formula IX:Formula VIII Formula IXf) react the compound of formula IX under de-alkylation conditions to form a compound of Formula X:Formula Xg) react the compound of formula X and formula XI under basic conditions to form a compound of Formula XII:Formula XI Formula XIIh) react the compound of formula XII under strong oxidation conditions to form a compound of Formula XIII:Formula XIIIi) react the compounds of formula XIII and formula XIV under mild condensation conditions to form a compound of Formula I:Formula XIV Formula I whereinn is an integer number selected from 0, 1 , 2, 3 or 4;m is an integer number selected from 0, 1 or 2;X is selected from nitrogen or C-H;Halo is selected from halogen;R is a racemate selected from C-alkyl linear or branched chain (C1-C20), 0-or NH-alkyl linear or branched chain (C1-C20); more preferably, R is selected from (S)-stereoisomers;Y is selected from nitrogen or C-H;Z is selected from C-alkyl linear or branched chain (C1-C20), N-alkyl linear or branched chain (C1-C20), oxygen, sulfur, sulfoxide or sulfone.ZH is selected from CH-alkyl linear or branched chain (C1-C20), NH-alkyl linear or branched chain (C1-C20), hydroxyl or thiol.G is selected from CH3, NH2, Oxygen-C alkyl linear or branched chain (C1-C10) and thio-alkyl linear or branched chain (C1-C10);MH is selected from CH3, NH2, hydroxyl and thiol;M is selected from CH2, nitrogen, oxygen, sulfur, sulfoxide or sulfone;L is selected from CH2, nitrogen, oxygen and sulfur;A is absent or selected from hydrogen, alkyl linear or branched chain (C1-C20);PG - is selected from any protecting group; preferably, PG is selected from acetyl, tosyl, silyl derivativesHis is a moiety selected from:

[0042] A third object of the present invention is a pharmaceutical composition comprising at least one compound of Formula I or a pharmaceutically acceptable salt thereof in a therapeutically effective amount and at least one pharmaceutically acceptable excipient.

[0043] Another object is a pharmaceutical combination comprising:i) at least one compound of general Formula I or any pharmaceutically acceptable salts thereof; andii) one or more agents selected from the list comprising a non-steroidalglucocorticoid receptor agonist or corticoids.

[0044] It is also provided a medicament comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, for use in treating a disease, said disease selected from the group comprising asthma, chronic obstructive pulmonary disease (COPD), rhinitis, irritable bowel syndrome (IBS), spastic colitis, histamine intolerance, functional dyspepsia, eosinophilic esophagitis, gastroesophageal reflux disease (GERD), food intolerance and food allergy, and dermatitis, such as atopic dermatitis and allergic urticaria.

[0045] Another object provided is an use of at least one compound of general Formula I or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating a disease being selected from the group comprising asthma, chronic obstructive pulmonary disease (COPD), rhinitis, irritable bowel syndrome (IBS), spastic colitis, histamine intolerance, functional dyspepsia, eosinophilic esophagitis, gastroesophageal reflux disease (GERD), food intolerance and food allergy, and dermatitis, such as atopic dermatitis and allergic urticaria..

[0046] Another object provided herein is a method of treating a disease comprising the administration of a therapeutically effective amount of at least one compound of general Formula I or a pharmaceutically acceptable salt thereof, to a patient in need.

[0047] Another aspect of the invention is a method for alleviating symptoms of a disease or condition in a subject, comprising the administration of an effective amount of a compound or a pharmaceutically acceptable salt thereof, and wherein the disease or condition is selected from the group comprising asthma, chronic obstructive pulmonary disease (COPD), rhinitis, irritable bowel syndrome (IBS), spastic colitis, histamine intolerance, functional dyspepsia, eosinophilic esophagitis, gastroesophageal reflux disease (GERD), food intolerance and food allergy, and dermatitis, such as atopic dermatitis and allergic urticaria.Detailed Description of the InventionDefinitions

[0048] Unless otherwise stated, the following terms used in the specification and claims shall have the following meanings for the purposes of this application.

[0049] It is noted that, as used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural references unless the context clearly dictates otherwise. Further, definitions of standard chemistry terms may be found in reference works, including Carey and Sundberg “Advanced Organic Chemistry 4™ Ed.” Vols. A (2000) and B (2001), Plenum Press, New York. Also, unless otherwise indicated, conventional methods of mass spectroscopy, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA techniques and pharmacology, within the skill of the art are employed.

[0050] “Pharmaceutically acceptable” means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary use as well as human pharmaceutical use.

[0051] “Pharmaceutically acceptable salts” means salts of compounds of the present invention which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity. Such salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc; or with organic acids such as acetic acid, propionic acid, hexanoic acid, heptanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, o-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2- ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]oct-2-ene-1 -carboxylic acid, glucoheptonic acid, 4, 4'-methylenebis(3-hydroxy-2-ene-1 -carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid etc.

[0052] Pharmaceutically acceptable salts also include base addition salts which may be formed when acidic protons present are capable of reacting withinorganic or organic bases. Acceptable inorganic bases include sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide and calcium hydroxide. Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine etc.

[0053] “Leaving group” means the group with the meaning conventionally associated with it in synthetic organic chemistry, i.e. , an atom or group displaceable under reaction (e.g., alkylating) conditions. Examples of leaving groups include, but are not limited to, halo (e.g., F, Cl, Br and I), alkyl (e.g., methyl and ethyl) and sulfonyloxy (e.g., mesyloxy, ethanesulfonyloxy, benzenesulfonyloxy and tosyloxy), thiomethyl, thienyloxy, dihalophosphinoyloxy, tetrahalophosphoxy, benzyloxy, isopropyloxy, acyloxy, etc.

[0054] “Subject” and “patient” includes humans, non-human mammals (e.g., dogs, cats, rabbits, cattle, horses, sheep, goats, swine, deer, etc) and nonmammals (e.g., birds, etc).

[0055] “Sulfonyl” means the radical -SO2- and / or -SO2-R, wherein R is hydrogen or a further substituent. It is noted that the sulfonyl radical may be further substituted with a variety of substituents to form different sulfonyl groups including sulfonic acids, sulfonamides, sulfonate esters, and sulfones.

[0056] “Therapeutically effective amount” means that amount which, when administered to an animal for treating a disease, is sufficient to effect such treatment for the disease.

[0057] “Thio” denotes replacement of an oxygen by a sulfur and includes, but is not limited to, -SR, -S- and =S containing groups.

[0058] “Thioalkyl” means an alkyl, as defined above, except where one or more of the carbon atoms forming the alkyl chain are replaced with sulfur atoms (- S- or -S-R, wherein R is hydrogen or a further substituent). For example, a thio(C1 -10)alkyl refers to a chain comprising between I and 10 carbons and one or more sulfur atoms.

[0059] The present invention discloses a novel treatment method for rhinitis by combining two distinct pharmacological classes: Histamine receptorantagonists and muscarinic receptor antagonists. Muscarinic receptor antagonists, such as ipratropium, umeclidinium, tiotropium and glycopirrolate, block the action of acetylcholine via the muscarinic receptors, reducing the abdominal pain of IBS patients or the production of nasal secretions and relieving symptoms like rhinorrhea.

[0060] The invention comprises a chemical compound characterized by its structure, pharmacological properties, and mode of administration. This single molecule is capable of binding to Histamine receptors, and simultaneously binding to muscarinic receptors, exerting antagonist effects.

[0061] A first aspect of the present invention involves a compound represented by the chemical structure Formula I or its pharmaceutically acceptable salts:

[0062] [Chem. 1] - Formula Iwherein,X is selected from nitrogen or C-H;n = is an integer number selected from 0, 1 , 2, 3 or 4;m = is an integer number selected from 0, 1 or 2;R is a racemate selected from C-alkyl linear or branched chain (C1-C20), O- or A / / - / -alkyl linear or branched chain (C1-C20);Y is selected from nitrogen or C-H;Z is selected from CH2, C-alkyl linear or branched chain (C1-C20), / V-alkyl linear or branched chain (C1-C20), oxygen, sulfur, sulfoxide or sulfone.M is selected from CH2, nitrogen, oxygen, sulfur, sulfoxide or sulfone;L is selected from CH2, nitrogen, oxygen or sulfur;A is absent or selected from hydrogen, alkyl linear or branched chain (C1-C20);His is a moiety selected from:

[0063] In an embodiment, X is N; R is CH3; Z is SO2; M is 0; L is N; A is H and / or n is 4.

[0064] In an embodiment, the salt is a halogen salt, preferably hydrochloride or bromide salt.

[0065] In an embodiment, R is optionally selected from (S)-stereoisomers.

[0066] In an embodiment, the compound of formula I is selected from:• 3-(3-((5-((S)-1 -(4-cycloheptylpiperazin-1 -y l)ethy I )py ridi n-2- yl)sulfonyl)phenoxy)-N-(4-((((S)-2-hydroxy-3-(naphthalen-1- yloxy)propyl)amino)methyl)phenyl)propenamide• (S)-N-(4-(((2-(benzhydryloxy)ethyl)amino)methyl)phenyl)-3-(3-((5-(1-(4- cycloheptylpiperazin-1-yl)ethyl)pyridin-2- yl)sulfonyl)phenoxy)propenamide• (S)-N-(4-((4-(6-chloro-1 H-benzo[d]imidazole-2-carbonyl)piperazin-1 - yl)methyl)phenyl)-3-(3-((5-(1-(4-cycloheptylpiperazin-1-yl)ethyl)pyridin-2- yl)sulfonyl)phenoxy)propenamide• (S)-3-(3-((5-(1 -(4-cycloheptylpiperazin-1 -y l)ethy I )pyrid in-2- yl)sulfonyl)phenoxy)-N-(4-((4-(1-(2-ethoxyethyl)-1H-benzo[d]imidazol-2- yl)-1 ,4-diazepan-1 -yl)methyl)phenyl)propenamide• (S)-3-(3-((5-(1 -(4-cycloheptylpiperazin-1 -y l)ethy I )pyrid in-2- yl)sulfonyl)phenoxy)-N-(4-((4-((1-(4-fluorobenzyl)-1 H-benzo[d]imidazol-2- yl)amino)piperidin-1-yl)methyl)phenyl)propenamide• (S)-3-(3-((4-(1 -(4-cycloheptylpiperazin-1 - yl)ethyl)phenyl)sulfonyl)phenoxy)-N-(4-((4-(1-(2-ethoxyethyl)-1H- benzo[d]imidazol-2-yl)piperidin-1-yl)methyl)phenyl)propenamide• (S)-3-(3-((5-(1 -(4-cycloheptylpiperazin-1 -y l)ethy I )pyrid in-2- yl)sulfonyl)phenoxy)-N-(4-((4-(1-(2-ethoxyethyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methyl)phenyl)propenamide• N-(4-((((R)-2-(3-chlorophenyl)-2-hydroxyethyl)amino)methyl)phenyl)-3-(3- ((5-((S)-1 -(4-cycloheptylpiperazin-1 -y l)ethy I )py rid in-2- yl)sulfonyl)phenoxy)propenamide• (S)-N-(4-((4-(benzhydryloxy)piperidin-1 -yl)methyl)phenyl)-3-(3-((5-(1 -(4- cycloheptylpiperazin-1-yl)ethyl)pyridin-2- yl)sulfonyl)phenoxy)propenamide• (S)-N-(4-(3-(4-(8-chloro-5,6-dihydro-11 H-benzo[5,6]cyclohepta[1 ,2- b]py ridi n-11 -y I idene)piperidin-1 -yl)propyl)phenyl)-3-(3-((5-(1 -(4- cycloheptylpiperazin-1-yl)ethyl)pyridin-2- yl)sulfonyl)phenoxy)propenamide• (S)-N-(4-((4-(8-chloro-5,6-dihydro-11 H-benzo[5,6]cyclohepta[1 ,2- b]py ridi n-11 -y I idene)piperidin-1 -yl)methyl)phenyl)-3-(3-((5-(1 -(4- cycloheptylpiperazin-1-yl)ethyl)pyridin-2- yl)sulfonyl)phenoxy)propenamide.

[0067] The present invention also provides a process to obtain the compound of Formula I defined in the first aspect, comprising the steps of:a) reacting compounds of formulas II and III under basic condition to obtain a product comprising the formula IV:Formula II Formula III Formula IVb) if Z in Formula IV is sulfur, optionally react compound of formula IV with an oxidant prior to step c);c) react a compound of formula IV under reductant conditions, followed by protection reaction with the remaining alcohol residue, that form a product comprising the formula V:d) react the compounds of formula V and VI under mild conditions, followed by deprotection group under acidic conditions to form a compound of Formula VII:Formula VIIe) react the compounds of formula VII and VIII under reductive amination conditions to form a compound of Formula IX:Formula VIII Formula IXf) react the compound of formula IX under de-alkylation conditions to form a compound of Formula X:Formula Xg) react the compound of formula X and formula XI under basic conditions to form a compound of Formula XII:Formula XI Formula XIIh) react the compound of formula XII under strong oxidation conditions to form a compound of Formula XIII:Formula XIIIi) react the compounds of formula XIII and formula XIV under mild condensation conditions to form a compound of Formula I:Formula XIV Formula I whereinn is an integer number selected from 0, 1 , 2, 3 or 4;m is an integer number selected from 0, 1 or 2;X is selected from nitrogen or C-H;Halo is selected from halogen;R is a racemate selected from C-alkyl linear or branched chain (C1-C20), 0- or NH-alkyl linear or branched chain (C1-C20); more preferably, R is selected from (S)-sterioisomers;Y is selected from nitrogen or C-H;Z is selected from C-alkyl linear or branched chain (C1-C20), N-alkyl linear or branched chain (C1-C20), oxygen, sulfur, sulfoxide or sulfone.ZH is selected from CH-alkyl linear or branched chain (C1-C20), NH-alkyl linear or branched chain (C1-C20), hydroxyl or thiol.G is selected from CH3, NH2, Oxygen-C alkyl linear or branched chain (C1-C10) and thio-alkyl linear or branched chain (C1-C10);MH is selected from CH3, NH2, hydroxyl and thiol;M is selected from CH2, nitrogen, oxygen, sulfur, sulfoxide or sulfone;L is selected from CH2, nitrogen, oxygen and sulfur;A is absent or selected from hydrogen, alkyl linear or branched chain (C1-C20);PG - is selected from any protecting group; preferably, PG is selected from acetyl, tosyl, silyl derivativesHis is a moiety selected from:

[0068] In an optional embodiment, a salt of the compound of Formula I is obtained from the reaction of the compound of Formula I with an inorganic acid in the presence of an organic solvent.

[0069] Said inorganic acid is selected from the group comprising halogen acids, preferably HBr or HCI.

[0070] The organic solvent is an aprotic solvent selected from the group comprising 1,4-dioxane or acetonitrile.

[0071] In an optional embodiment, the salt precipitation is filtered under reduced pressure; and the solid obtained is left to air dry.

[0072] In an optional embodiment, the racemate derivative from compound of formula IX obtained from step e) can be separated via SFC-separation procedure before proceeding to step f), wherein the enantiomer (S) is preferably used.

[0073] In another embodiment, the compound of formula XIV is optionally obtained by reacting compounds of formula XV and formula XVI under reductive amination condition:Formula XV Formula XVIwherein A, L, His and m are as defined in the second object.

[0074] A third object of the present invention is a pharmaceutical composition comprising at least one compound of Formula I or a pharmaceutically acceptable salt thereof in a therapeutically effective amount and at least one pharmaceutically acceptable excipient.

[0075] In an embodiment, the pharmaceutical composition is administered orally, intranasally or via inhalation.

[0076] In another embodiment, the composition is formulated as a liquid suspension, a nasal spray, or inhaler.

[0077] Another object is a pharmaceutical combination comprising:i) at least one compound of general Formula I or any pharmaceutically acceptablesalts thereof; andii) one or more agents selected from the list comprising a non-steroidal glucocorticoid receptor agonist or corticoid.

[0078] It is also provided a medicament comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, for use in treating a disease, said disease being selected from the group comprising asthma, chronic obstructive pulmonary disease (COPD), rhinitis, irritable bowel syndrome (IBS), spastic colitis, histamine intolerance, functional dyspepsia, eosinophilic esophagitis, gastroesophageal reflux disease (GERD), food intolerance and food allergy, and dermatitis, such as atopic dermatitis and allergic urticaria.

[0079] In an embodiment, the medicament is preferably used for treating respiratory diseases, such as asthma, COPD or rhinitis.

[0080] In an embodiment, the medicament is for human or veterinary use.

[0081] Another object provided is an use of at least one compound of general Formula I or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating a disease selected from the group comprising asthma, chronic obstructive pulmonary disease (COPD), rhinitis, irritable bowel syndrome (IBS), spastic colitis, histamine intolerance, functional dyspepsia, eosinophilic esophagitis, gastroesophageal reflux disease (GERD), food intolerance and food allergy, and dermatitis, such as atopic dermatitis and allergic urticaria.

[0082] In an embodiment, the use is for the manufacture of a medicament for the treatment of respiratory diseases, said respiratory disease comprising asthma, COPD and rhinitis.

[0083] In another embodiment, the use is for a human or veterinary disease.

[0084] Another object provided herein is a method of treating a disease comprising the administration of a therapeutically effective amount of at least one compound of general Formula I or a pharmaceutically acceptable salt thereof, to a patient in need.

[0085] In an embodiment, the method comprises the treatment of a disease selected from the group comprising selected from the group comprisingasthma, chronic obstructive pulmonary disease (COPD), rhinitis, irritable bowel syndrome (IBS), spastic colitis, histamine intolerance, functional dyspepsia, eosinophilic esophagitis, gastroesophageal reflux disease (GERD), food intolerance and food allergy, and dermatitis, such as atopic dermatitis and allergic urticaria.

[0086] In an embodiment, the therapeutically effective amount of the compound of general Formula I is from 0.0001 to 10,000 mg, optionally from 0.001 to 5,000 mg.

[0087] In another embodiment, the compound of formula I is administered orally, intranasally or via inhalation.

[0088] In another embodiment, the patient is a human or animal.

[0089] Thus, the present invention solves the technical problem by providing a novel dual acting compound addressing gastro and respiratory disorders with a single medication, where the simultaneous inhibition of Histamine receptors and inhibition of muscarinic receptors result in a synergistic effect, enhancing the overall efficacy of the compound. Other potential advantages of the invention include:

[0090] Rapid Onset: muscarinic receptor antagonists reduce nasal secretions, leading to a faster onset of action.

[0091] Reduced Side Effects: Combining drugs with complementary mechanisms of action may allow for lower doses of each component, potentially reducing the risk of side effects associated with high-dose monotherapy.

[0092] Simplified Treatment: Patients can benefit from a more straightforward treatment regimen, potentially leading to improved compliance and better symptom management.

[0093] Reduced Side Effects: Lower doses of each active component may be used, reducing the risk of side effects commonly associated with higher- dose monotherapy.

[0094] Thus, the present invention provides a single molecule comprising a histamine receptor antagonist and a muscarinic receptor antagonist offeringa novel and promising approach to treating gastro and respiratory disorders. These innovative compounds provide a comprehensive solution for addressing multiple histamine and muscarinic-related symptoms in a simplified and effective manner, ultimately improving the quality of life for individuals suffering from gastro and / or respiratory disorders, including but not limited to asthma, chronic obstructive pulmonary disease (COPD), rhinitis, irritable bowel syndrome (IBS), spastic colitis, histamine intolerance, functional dyspepsia, eosinophilic esophagitis, gastroesophageal reflux disease (GERD), food intolerance and food allergy, and dermatitis, such as atopic dermatitis and allergic urticaria.

[0095] The following examples are illustrative and do not limit the scope of the present invention.EXAMPLESPreparation of example compoundsPreparation of compound 3"1 3

[0096] To a solution of compound 1 (9 g, 64.19 mmol, 7.89 mL, 1 eq) and compound 2 (8.87 g, 64.19 mmol, 7.78 mL, 1 eq) in DMF (90 mL) was added CS2CO3 (41.83 g, 128.39 mmol, 2 eq). The mixture was stirred at 80 °C for 0.5 hour. The reaction solution was poured into water (100 mL) and extracted with ethyl acetate (100 mL x 3). The combined organic layers were washed with brine (100 mL x 3) and dried over Na2SO4. Then the mixture was filtered, and the filtrate was concentrated under vacuum to give a residue. The residue was purified by column chromatography (SiC>2, Petroleum ether / Ethyl acetate=100 / 1 to 10 / 1). Compound 3 (16.2 g, 60.75 mmol, 94.64% yield, 96.88% purity) was obtained as a yellow oil.

[0097] LCMS: Rt=0.908 min; [M+H]+=259.1Preparation of compound 4

[0098] To a solution of compound 3 (15.2 g, 58.84 mmol, 1 eq) in EtOH (150 mL) was added NaBH4 (3.65 g, 96.48 mmol, 1.64 eq). The mixture was stirred at 25 °C for 1 h. The reaction mixture was quenched by addition of saturated NH4CI (50 mL) at 0 °C, then diluted with water (10 mL), concentrated under reduced pressure to remove EtOH. The resulting mixture was extracted with ethyl acetate (100 mL x 3), the combined organic layers were washed with brine (100 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether / Ethyl acetate=100 / 1 to 3 / 1). Compound 4 (16.4 g, 60.66 mmol, 51.55% yield, 96.3% purity) was obtained as a yellow oil.

[0099] 1H NMR (400 MHz, CDCI3) 5 = 7.39 - 7.35 (m, 2H), 7.35 - 7.32 (m, 2H), 7.22 (t, J = 8.0 Hz, 1 H), 6.92 - 6.88 (m, 1 H), 6.87 (t, J = 2.0 Hz, 1 H), 6.79 (td, J = 1.2, 8.3 Hz, 1 H), 4.95 - 4.85 (m, 1 H), 3.77 (s, 3H), 1.80 (br s, 1 H), 1.50 (d, J = 6.4 Hz, 3H).Preparation of compound 54 5

[0100] To a solution of compound 4 (15.4 g, 59.15 mmol, 1 eq) in DCM (154 mL) was added m-CPBA (24.02 g, 118.30 mmol, 85% purity, 2 eq) at 0 °C. The mixture was stirred at 25 °C for 16 hours. The reaction mixture was quenched by addition saturated Na2SOs aqueous (100 mL) at 0 °C, then diluted with water (100 mL) and extracted with ethyl acetate (200 mL x 2). The combined organic layers were washed with saturated NaHCOs aqueous solution (100 mL x 3) and brine (100 mL x 3), dried over Na2SO4, filtered andconcentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiC>2, Petroleum ether / Ethyl acetate=10 / 1 to 1 / 1). Compound 5 (15 g, 49.77 mmol, 84.14% yield, 97% purity) was obtained as a white solid.

[0101] LCMS: Rt=0.745 min; [M+H]+=293.1Preparation of compound 65 6

[0102] To a solution of compound 5 (14 g, 47.89 mmol, 1 eq) and TEA (14.54 g, 143.66 mmol, 20.00 mL, 3 eq) in DCM (140 mL) was added methylsulfonyl methanesulfonate (12.51 g, 71.83 mmol, 1.5 eq). The mixture was stirred at 25 °C for 4 hours. The reaction mixture was poured into H2O (50 mL) and extracted with DCM (50 mL x 3). The combined organic layers were washed with brine (50 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The crude product was used in the next step without further purification. Compound 6 (17 g, crude) was obtained as a yellow oil.

[0103] LCMS: Rt=0.794 min.Preparation of compound 86 8

[0104] To a solution of compound 6 (17 g, 45.89 mmol, 1 eq) in ACN (150 mL) was added TMP (7.78 g, 55.07 mmol, 9.35 mL, 1.2 eq) and 7 (9.40 g, 50.48 mmol, 1.1 eq). The mixture was stirred at 25 °C for 16 hours. The reaction mixture was concentrated under reduced pressure to give a residue. Theresidue was purified by column chromatography (SiC>2, Petroleum ether / Ethyl acetate=10 / 1 to 1 / 1). Compound 8 (20 g, 39.64 mmol, 86.38% yield, 91.29% purity) was obtained as a yellow oil.

[0105] 1H N MR (400 MHz, CDCIs) 5 = 7.88 (d, J = 8.4 Hz, 2H), 7.54 - 7.51 (m, 1 H), 7.49 - 7.45 (m, 3H), 7.41 (t, J = 8.0 Hz, 1 H), 7.09 (ddd, J = 0.8, 2.6, 8.3 Hz, 1 H), 3.85 (s, 3H), 3.43 - 3.35 (m, 5H), 2.45 - 2.23 (m, 4H), 1.43 (s, 9H), 1.31 (d, J = 6.8 Hz, 3H).Preparation of compound 9

[0106] A mixture of compound 8 (20 g, 43.42 mmol, 1 eq) in dioxane (20 mL) was added HCI / dioxane (4 M, 108.56 mL, 10 eq) was stirred at 25 °C for 0.5 hour. The reaction mixture was concentrated under vacuum to give the crude product. The crude product was used in the next step without further purification. Compound 9 (20.3 g, crude) was obtained as a white solid.

[0107] LCMS: Rt=0.757 min; [M+H]+=361.2Preparation of compound 119 11

[0108] A mixture of compound 9 (20.3 g, 56.32 mmol, 1 eq) and 10 (63.17 g, 563.15 mmol, 66.42 mL, 10 eq) in MeOH (200 mL) was stirred at 25 °C for 0.5 hour. Then NaBHsCN (17.69 g, 281.58 mmol, 5 eq) was added at 25 °C and the mixture was stirred for 30 hours. The reaction mixture was poured into H2O (100 mL) and MeOH was removed under reduced pressure. Then the mixture was extracted with ethyl acetate (150 mL x 3). The combined organic layers were washed with brine (150 mL x 3), dried over Na2SO4,filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiC>2, DCM: MeOH=100 / 1 to 10 / 1). Compound 11 (16.5 g, 33.25 mmol, 59.05% yield, 92.03% purity) was obtained as a yellow oil.

[0109] 1H NMR (400 MHz, CDCIs) 5 = 7.89 (d, J = 8.4 Hz, 2H), 7.52 (d, J = 7.9 Hz, 1 H), 7.49 - 7.39 (m, 4H), 7.10 (dd, J = 2.0, 7.9 Hz, 1 H), 3.86 (s, 3H), 3.51 - 3.48 (m, 1 H), 3.03 - 2.87 (m, 5H), 2.74 - 2.52 (m, 3H), 2.07 - 1.86 (m, 3H), 1.76 (br d, J = 7.2 Hz, 2H), 1.60 - 1.50 (m, 8H), 1.32 (d, J = 6.8 Hz, 3H) Preparation of compound 12

[0110] To a solution of compound 11 (2.00 g, 4.38 mmol, 1 eq) in DCM (50 mL) was added BBrs (5.49 g, 21.90 mmol, 2.11 mL, 5 eq) at 0 °C. Then the mixture was stirred at 25 °C for 1 hour. The reaction mixture was quenched with NHs / MeOH (0.5 M, 30 mL), and partitioned between water (20 mL), and ethyl acetate (20 mL x 3). The combined organic layers were washed with brine (20 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiC>2, DCM: MeOH =100 / 1 to 10 / 1). Compound 12 (5.8 g, 12.38 mmol, 70.66% yield, 94.47% purity) was obtained as a white solid.

[0111] LCMS: Rt=0.457 min; [M+H]+=443.2Preparation of compound 13

[0112] Compound 12 (5.8 g, 12.38 mmol, 1 eq) was purified by chiral SFC (column: Phenomenex-Cellulose-2 (250mm x 50mm, 10um); mobile phase:[MeOH-ACN];B%: 60%-60%,4.3min). Compound 13 (2 g, 4.51 mmol, 39.94% yield, 99.85% purity) was obtained as a white solid.

[0113] Compound 13

[0114] 1H NMR (400 MHz, CDCIs) 5 = 7.80 (d, J = 8.4 Hz, 2H), 7.42 - 7.34 (m, 3H), 7.33 - 7.27 (m, 2H), 6.96 (dd, J = 1.6, 8.0 Hz, 1 H), 3.48 (s, 1 H), 3.35 (q, J = 6.8 Hz, 1 H), 2.60 - 2.33 (m, 8H), 1.88 - 1.76 (m, 2H), 1.73 - 1.60 (m, 2H), 1.56 - 1.32 (m, 8H), 1.28 (d, J = 6.8 Hz, 3H)Preparation of compound 1413 14

[0115] To a solution of compound 13 (1.60 g, 3.61 mmol, 1 eq) in MeCN (16 mL) was added K2CO3 (1.50 g, 10.82 mmol, 3 eq) and 3-hydroxypropyl 4- methylbenzenesulfonate (1.08 g, 4.69 mmol, 1.3 eq). The mixture was stirred at 80 °C for 5 hours. The reaction mixture was poured into water (30 mL) and extracted with ethyl acetate (30 mL x 2). The combined organic layers were washed with brine (30 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150x40mmx 15um; mobile phase: [water(FA)-ACN];B%: 15%-45%,10min). Compound 14 (1.1 g, 2.20 mmol, 60.89% yield, 99.99% purity) was obtained as a white solid.

[0116] LCMS: Rt=0.810 min; [M+H]+=501.3Preparation of compound Intermediate 1

[0117] To a solution of compound 14 (1 g, 2.00 mmol, 1 eq) in acetone (10 mL) was added sulfuric acid trioxochromium (2.7 M, 739.72 pL, 1 eq) at 0 °C. The mixture was stirred at 25 °C for 2 hrs. After quenching the excess oxidant with i-PrOH (2 mL), the solid was washed with DCM (20 mL) andacetone (20 mL). The pH was adjusted to 7 with saturated Na2COs aqueous solution, the mixture was filtered and concentrated under vacuum. The residue was purified by prep-HPLC (column: YMC Triart C18 150x25mmx5um; mobile phase: [water (HCI)-ACN]; B%: 20%-50%,10min). Intermediate 1 (410 mg, 796.54 pmol, 39.88% yield, 99.99% purity) was obtained as a white solid.

[0118] LCMS: Rt=0.483 min; [M+H]+=515.3Preparation of compound 16> ""< "1 16

[0119] To a solution of compound 1 (6.5 g, 46.36 mmol, 5.70 mL, 1 eq) and compound 15 (9.27 g, 46.36 mmol, 1 eq) in DMF (70 mL) was added CS2CO3 (45.32 g, 139.08 mmol, 3 eq). The mixture was stirred at 80 °C for 1 hour. The reaction solution was poured into saturated NH4CI aqueous solution (100 mL) and extracted with ethyl acetate (200 mL x 2). The combined organic layers were washed with brine (100 mL x 3) and dried over Na2SO4. Then the mixture was filtered, and the filtrate was concentrated under vacuum. The crude product was used directly in the next step without further purification. Compound 16 (13.8 g, crude) was obtained as a yellow solid.

[0120] 1H NMR (400 MHz, CDCI3) 5 = 8.95 (d, J = 1.8 Hz, 1H), 7.99 (dd, J = 2.4, 8.4 Hz, 1H), 7.43 - 7.36 (m, 1H), 7.21 (d, J = 7.6 Hz, 1H), 7.18 - 7.13 (m, 1H), 7.03 (td, J = 1.2, 8.4 Hz, 1H), 6.94 (d, J = 8.4 Hz, 1H), 3.83 (s, 3H), 2.57 (s, 3H).Preparation of compound 1716 17

[0121] To a solution of compound 16 (10 g, 38.56 mmol, 1 eq) in MeOH (100 mL) was added NaBH4 (2.05 g, 54.05 mmol, 1.40 eq) at 0 °C. The mixture was stirred at 25 °C for 1 hour. The reaction mixture was quenched by addition 1 N HCI (100 mL) at 0 °C, then diluted with water (100 mL) and remove MeOH under vacuum. Then extracted with ethyl acetate (200 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether / Ethyl acetate=100 / 1 to 2 / 1). Compound 17 (9.8 g, 35.62 mmol, 92.38% yield, 95% purity) was obtained as a yellow solid.

[0122] 1H NMR (400 MHz, CDCIs) 5 = 8.42 (d, J = 2.0 Hz, 1H), 7.54 (dd, J = 2.0, 8.4 Hz, 1H), 7.38 - 7.31 (m, 1H), 7.17 (d, J = 7.6 Hz, 1H), 7.15 - 7.10 (m, 1 H), 7.00 - 6.91 (m, 2H), 4.96 - 4.88 (m, 2H), 3.82 (s, 3H), 1.50 (d, J = 6.4 Hz, 3H).Preparation of compound 1817 18

[0123] To a solution of compound 17 (8.8 g, 33.67 mmol, 1 eq) in MeCN (25 mL) was added a solution of NalO4 (15.12 g, 70.71 mmol, 3.92 mL, 2.1 eq) and RuCh (698.47 mg, 3.37 mmol, 224.59 mL, 0.1 eq) in CCk (25 mL) and H2O (5 mL) at 0 °C. Then the mixture was stirred at 25 °C for 1 hour. The reaction mixture was quenched by addition saturated Na2SOs aq. (50 mL) at 0 °C, then diluted with water (100 mL) and ethyl acetate (100 mL). The aqueous phase was extracted with ethyl acetate (100 mL x 2). Combined extracts were washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated under vacuum to give a residue. The residue was purified by column chromatography (SiC>2, Petroleum ether / Ethyl acetate=100 / 1 to 1 / 1). Compound 18 (9.8 g, 33.07 mmol, 98.22% yield, 99% purity) was obtained as a yellow solid.

[0124] 1H NMR (400 MHz, CDCIs) 6 = 8.66 (d, J = 2.0 Hz, 1 H), 8.15 (d, J = 8.0 Hz, 1 H), 7.95 (dd, J = 2.0, 8.0 Hz, 1 H), 7.62 (d, J = 8.0 Hz, 1 H), 7.59 - 7.54 (m, 1H), 7.43 (t, J = 8.0 Hz, 1H), 7.13 (dd, J = 2.0, 8.4 Hz, 1H), 5.03 (q, J = 6.4 Hz, 1H), 3.87 (s, 3H), 2.33 -2.06 (m, 1H), 1.52 (d, J = 6.4 Hz, 3H).Preparation of compound 1918 19

[0125] To a solution of compound 18 (8.8 g, 30.00 mmol, 1 eq) and TEA (9.11 g, 90.00 mmol, 12.53 mL, 3 eq) in DCM (90 mL) was added MsCI (8.02 g, 70.01 mmol, 5.42 mL, 2.33 eq) at 0 °C. The mixture was stirred at 0 °C for 1 hour. The reaction mixture was poured into ice water (100 mL) and extracted with ethyl acetate (200 mL x 2). The combined organic layers were washed with brine (100 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The crude product was used directly in the next step without further purification. Compound 19 (13.5 g, crude) was obtained as yellow solid.

[0126] LCMS: Rt=0.823 min; [M+H]+=371.9Preparation of compound 2019 20

[0127] To a solution of compound 19 (13.5 g, 36.35 mmol, 1 eq) in ACN (150 mL) was added TMP (7.70 g, 54.52 mmol, 9.26 mL, 1.5 eq) and tert-butyl piperazine-1 -carboxylate (compound 7) (8.80 g, 47.25 mmol, 1.3 eq). The mixture was stirred at 80 °C for 12 hours. The reaction mixture was concentrated under vacuum to give a residue. Then, ethyl acetate (200 mL) and water (200 mL) were added, and layers were separated. The aqueousphase was extracted with ethyl acetate (200 mL x 2). Combined extracts were washed with brine (200 mL), dried over Na2SO4, filtered, and concentrated under vacuum to give a residue. The residue was purified by column chromatography (SiC>2, Petroleum ether / Ethyl acetate=10 / 1 to 1 / 1). Compound 20 (10.6 g, 22.74 mmol, 62.55% yield, 99% purity) was obtained as yellow oil.

[0128] 1H NMR (400 MHz, CDCIs) 5 = 8.63 (d, J = 2.0 Hz, 1H), 8.14 (d, J = 8.0 Hz, 1 H), 7.89 (dd, J = 2.0, 8.0 Hz, 1 H), 7.64 (td, J = 1.2, 8.0 Hz, 1 H), 7.61 - 7.57 (m, 1 H), 7.44 (t, J = 8.0 Hz, 1 H), 7.14 (ddd, J = 0.8, 2.8, 8.2 Hz, 1 H), 3.87 (s, 3H), 3.51 (q, J = 6.8 Hz, 1H), 3.39 (d, J = 3.6 Hz, 4H), 2.43 (br s, 2H), 2.35 - 2.22 (m, 2H), 1.53 - 1.39 (m, 9H), 1.34 (d, J = 6.8 Hz, 3H).Preparation of compound 21

[0129] A mixture of compound 20 (10.2 g, 22.10 mmol, 1 eq) and HCI / dioxane (100 mL) and MeOH (30 mL) was stirred at 25 °C for 0.5 hour. The reaction mixture was concentrated under vacuum to give the crude product. The crude product was used directly in the next step without further purification. Compound 21 (10.6 g, crude, HCI) was obtained as a yellow solid.

[0130] LCMS: Rt=0.698 min; [M+H]+=362.0Preparation of compound 22<>21 22

[0131] A mixture of compound 21 (9.6 g, 26.56 mmol, 1 eq), DIEA (5.15 g, 39.84 mmol, 6.94 mL, 1.5 eq) and cycloheptanone (compound 10) (11.92 g, 106.24 mmol, 12.53 mL, 4 eq) in MeOH (100 mL) was stirred at 25 °C for0.5 hour. Then NaBHsCN (3.34 g, 53.12 mmol, 2 eq) was added at 25 °C and the mixture was stirred for 12 hours. The reaction mixture was poured into H2O (200 mL) and MeOH was removed under reduced pressure. Then, the residue was extracted with ethyl acetate (200 mL x 3). The combined organic layers were washed with brine (200 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiC>2, Petroleum ether / Ethyl acetate=10 / 1 to 1 / 10). Compound 22 (8.8 g, 18.27 mmol, 68.78% yield, 95% purity) was obtained as yellow solid.

[0132] 1H NMR (400 MHz, Methanol-d4) 5 = 8.64 (d, J = 2.0 Hz, 1H), 8.19 (d, J = 8.0 Hz, 1 H), 8.07 (dd, J = 2.0, 8.0 Hz, 1 H), 7.61 - 7.45 (m, 3H), 7.23 (ddd, J = 0.8, 2.4, 8.0 Hz, 1 H), 3.86 (s, 3H), 3.67 (q, J = 6.8 Hz, 1 H), 2.93 - 2.37 (m, 9H), 1.97 - 1.86 (m, 2H), 1.74 (tdd, J = 3.6, 6.8, 9.6 Hz, 2H), 1.64 - 1.32 (m, 13H).Preparation of compound 23b22 23a 23b

[0133] Compound 22 (2 g, 4.37 mmol, 1 eq) was purified by chiral SFC (column:DAICEL CHIRALPAK AD(250mmx30mm,10um);mobile phase:[0.1%NH3H2O MEOH];B%: 45%-45%,6.1min ; 105 min). Compound 23a (890 mg, 1.85 mmol, 42.28% yield, 95% purity) was obtained as a yellow solid. Compound 23b (940 mg, 1.85 mmol, 42.30% yield, 90% purity) was obtained as a yellow solid.

[0134] 1H NMR (400 MHz, Methanol-d4) 5 = 8.62 (d, J = 2.0 Hz, 1H), 8.18 (d, J = 8.0 Hz, 1H), 8.05 (dd, J = 2.0, 8.0 Hz, 1H), 7.60 - 7.46 (m, 3H), 7.26 - 7.19 (m, 1 H), 3.86 (s, 3H), 3.60 (q, J = 6.8 Hz, 1 H), 2.66 - 2.27 (m, 9H), 1.87 - 1.77 (m, 2H), 1.69 (dt, J = 4.0, 6.8 Hz, 2H), 1.61 - 1.32 (m, 11 H).Preparation of compound 24

[0135] To a solution of compound 23b (395 mg, 863.15 pmol, 1 eq) in DCM (50 mL) was added BBrs (1.30 g, 5.18 mmol, 499.01 pL, 6 eq) at 0 °C. Then the mixture was stirred at 20 °C for 2 hours. The reaction mixture was quenched with NHs / MeOH (0.5M, 40 mL) and the mixture was concentrated under vacuum to give a residue. The residue was purified by column chromatography (SiC>2, DCM / MeOH=50 / 1 to 10 / 1). Compound 24 (435 mg, 1.73 mmol, 99.98% yield, 88% purity) was obtained as a yellow solid.

[0136] 1H NMR (400 MHz, Methanol-d4) 5 = 8.67 (d, J = 1.6 Hz, 1H), 8.22 - 8.15 (m, 1H), 8.12 - 8.06 (m, 1 H), 7.49 - 7.32 (m, 3H), 7.10 - 7.01 (m, 1H), 3.78 (q, J = 6.8 Hz, 1 H), 3.28 - 3.10 (m, 5H), 2.93 - 2.37 (m, 3H), 2.12 - 2.01 (m, 2H), 1.86 - 1.47 (m, 12H), 1.41 (d, J = 6.8 Hz, 3H).Preparation of compound 2524 25

[0137] To a solution of 3-hydroxypropyl 4-methylbenzenesulfonate (467.67 mg, 2.03 mmol, 1.3 eq) in MeCN (1 mL) was added K2CO3 (647.74 mg, 4.69 mmol, 3 eq) and compound 24 (770 mg, 1.56 mmol, 90% purity, 1 eq). The mixture was stirred at 80 °C for 4 hours. The reaction mixture was poured into saturated NH4CI aqueous solution (50 mL) and extracted with ethyl acetate (50 mL x 2). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150x40mmx 15um; mobile phase: [water(FA)-ACN];B%: 10%-40%,10min). Compound 25 (560 mg, 1.06 mmol, 67.88% yield, 95% purity) was obtained as a yellow solid.

[0138] 1H NMR (400 MHz, Methanol-ck) 6 = 8.67 (d, J = 2.0 Hz, 1H), 8.49 (s, 1 H), 8.20 (d, J = 8.0 Hz, 1 H), 8.08 (dd, J = 2.0, 8.0 Hz, 1 H), 7.61 - 7.52 (m, 2H), 7.52 - 7.43 (m, 1H), 7.24 (ddd, J = 0.8, 2.4, 8.0 Hz, 1H), 4.15 (t, J = 6.4 Hz, 2H), 3.79 - 3.70 (m, 3H), 3.27 - 3.05 (m, 5H), 2.94 - 2.27 (m, 3H), 2.06 - 1.97 (m, 4H), 1.85 - 1.45 (m, 10H), 1.40 (d, J = 6.8 Hz, 3H).Preparation of compound 26

[0139] To a solution of compound 25 (200 mg, 365.16 pmol, 1 eq, FA) in acetone (10 mL) was added sulfuric acid trioxochromium (2.7 M, 676.2 pL, 5 eq) at 0 °C. The mixture was stirred at 25 °C for 3 hours. After quenching the excess oxidant with / -PrOH (5 mL), the mixture was adjusted to pH 7 with saturated Na2COs aqueous solution, and diluted with DCM / MeOH (30 mL, 5:1). The mixture of filtered by celite and concentrated under vacuum. DCM (20 mL) and water (20 mL) were added, and layers were separated. The aqueous phase was extracted with DCM (20 mL x 2). Combined extracts were dried over Na2SO4, filtered, and concentrated under vacuum to give a residue. The crude product was used directly in the next step without further purification. Compound 26 (120 mg, crude) was obtained as a yellow solid.

[0140] LCMS: Rt=0.771 min; [M+H]+=516.1Preparation of compound 2826 28

[0141] A mixture of 26 (200 mg, 387.85 pmol, 1 eq), compound 27 (70.47 mg, 581.77 pmol, 1.5 eq) and EDCI (111.53 mg, 581.77 pmol, 1.5 eq) in Pyridine (2.5 mL) was stirred at 28 °C for 1.5 h. The mixture was quenched with water (50 mL) and extracted with EtOAc (3 * 25 mL). The combined organiclayers were washed with brine (30 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was triturated with petroleum ether (30 mL) to give 3-[3-[[5-[(1 S)-1 -(4- cycloheptylpipetroluem etherrazin-1-yl)ethyl]-2-pyridyl]sulfonyl]phenoxy]-N- (4-formylphenyl)propanamide (205 mg, 281.60 pmol, 72.61% yield, 85% purity) as a light yellow solid.

[0142] LCMS: Rt = 0.541 min, m / z = 619.3 [M+H]+Preparation of ACH-00180028 ACH-001800

[0143] A mixture of compound 28 (105 mg, 169.69 pmol, 1 eq), compound 29 (68.56 mg, 220.59 pmol, 1.3 eq), NaBHsCN (31.99 mg, 509.06 pmol, 3 eq) and AcOH (10.19 mg, 169.69 pmol, 9.71 pL, 1 eq) in MeOH (1.5 mL) was stirred at 25 °C for 2 h. The mixture was quenched with NaHCOs (sat., aq., 20 mL) and extracted with EtOAc (3 * 10 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by Prep- HPLC (column: Phenomenex luna C18 150*25mm* 10um; mobile phase: [water (FA)-ACN]; gradient: 15%-45% B over 10 min) to give desired product (45 mg, 90% purity) as a white solid. After further purification by NPLC (column: Welch Ultimate XB-NH2250*50*10um; mobile phase: [Hexane- EtOH]; gradient: 15%-55% B over 15 min), desired product ACH-001800 (27.04 mg, 29.42 pmol, 59.73% yield, 99.4% purity) was obtained as a white solid.

[0144] 1H NMR (400 MHz, DMSO-d6) 5 = 10.04 (s, 1H), 8.62 (d, J = 1.6 Hz, 1H), 8.33 (dd, J = 1.2, 4.6 Hz, 1H), 8.17 (d, J = 8.1 Hz, 1H), 8.02 (dd, J = 2.0, 8.2 Hz, 1 H), 7.60 - 7.49 (m, 5H), 7.43 (s, 1 H), 7.32 (td, J = 2.1 , 7.3 Hz, 1 H), 7.28 (d, J = 2.0 Hz, 1 H), 7.25 - 7.14 (m, 4H), 7.06 (d, J = 8.2 Hz, 1 H),4.34 (br t, J = 5.7 Hz, 2H), 3.56 (q, J = 6.5 Hz, 1 H), 3.40 (s, 2H), 3.32 - 3.23 (m, 2H), 2.88 - 2.74 (m, 4H), 2.59 (br s, 2H), 2.46 - 2.27 (m, 9H), 2.26 - 2.09 (m, 6H), 1.65 (br d, J = 8.3 Hz, 2H), 1.61 - 1.53 (m, 2H), 1.53 - 1.30 (m, 8H), 1.27 (d, J = 6.7 Hz, 3H)

[0145] LCMS: Rt = 0.514 min, m / z = 913.5 [M+H]+Preparation of compound 32>30 32

[0146] A mixture of compound 30 (2 g, 6.27 mmol, 1 eq), compound 31 (1.67 g, 28.75 mmol, 1.96 mL, 4.59 eq), Pd(OAc)2 (422.09 mg, 1.88 mmol, 0.3 eq), NaHCOs (1.32 g, 15.67 mmol, 609.61 pL, 2.5 eq) and TBACI (1.74 g, 6.27 mmol, 1.75 mL, 1 eq), 4A MS (2 g) in / V, / V-dimethylformamide (10 mL) was degassed and purged with nitrogen for 3 times, and then the mixture was stirred at 55 °C for 6 h under nitrogen atmosphere. The reaction mixture was allowed to cool, and the mixture was filtered through diatomaceous earth. The filtrate was diluted with water (50 mL) and extracted with ethyl acetate (3 * 30 mL). The combined organic layers were washed with brine (2 * 100 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 20 g SepaFlash® Silica Flash Column, Eluent of 0~19% Ethyl acetate / Petroleum ether gradient at 75 mL / min) to afford Compound 32 (1.1 g, 4.32 mmol, 69.00% yield, 98% purity) as a white solid.

[0147] 1 H-NMR (400 MHz, CDCI3) 5 = 9.81 (t, J = 1.2 Hz, 1 H), 7.29 (d, J = 8.4 Hz, 2H), 7.12 (d, J = 8.4 Hz, 2H), 6.44 (br s, 1H), 2.95 - 2.88 (m, 2H), 2.78 - 2.72 (m, 2H), 1.52 (s, 9H)Preparation of compound 3332 33

[0148] To a solution of compound 32 (524 mg, 2.10 mmol, 1.1 eq), compound 29 (593.90 mg, 1.91 mmol, 1 eq) and AcOH (229.49 mg, 3.82 mmol, 218.77 pL, 2 eq) in Methanol (5 mL) was added NaBHsCN (360.23 mg, 5.73 mmol, 3 eq) at 0 °C. The mixture was stirred at 25 °C for 12 h. The reaction mixture was quenched by NH4CI (sat., aq., 50 mL) at 0 °C, and then extracted with ethyl acetate (3 * 25 mL). The combined organic layers were washed with brine (2 * 50 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-HPLC (column: Phenomenex luna C18 (250*70 mm, 10 urn); mobile phase: [water(FA)-ACN];gradient:20%-50% B over 18 min) to afford compound 33 (726 mg, 1.27 mmol, 66.34% yield, 95% purity) as a pink solid.

[0149] 1H-NMR (400 MHz, CDCI3) 5 = 8.38 (d, J = 4.2 Hz, 1H), 7.46 (d, J = 7.6 Hz, 1H), 7.30 (d, J = 8.2 Hz, 2H), 7.20 (s, 1H), 7.17 - 7.12 (m, 2H), 7.10 (d, J = 8.2 Hz, 2H), 7.05 (d, J = 8.2 Hz, 1 H), 6.46 (s, 1 H), 3.39 - 3.28 (m, 2H), 3.21 -2.94 (m, 4H), 2.90 - 2.64 (m, 10H), 2.17 -2.07 (m, 2H), 1.53 (s, 9H)

[0150] LCMS: Rt=0.496 min; [M+H]+=544.4Preparation of compound 3433 34

[0151] To a solution of compound 33 (726 mg, 1.33 mmol, 1 eq) in Ethyl acetate (1 mL) was added HCI / dioxane (2 M, 6.67 mL, 10 eq) at 25 °C. The mixture was stirred at 30 °C for 4 h. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was added NaHCOs (sat., aq., 20 mL) and extracted with Ethyl acetate (20 mL x 3). The combined organic layers were washed with brine (30 mL x 2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The crude product was triturated with Petroleum ether (10 mL) at 25 °C for 10 min to afford compound 34 (321 mg, 520.53 pmol, 39.01% yield, 72% purity) as a pink solid.

[0152] LCMS: Rt=0.408 min; [M+H]+=444.3Preparation of ACH-00180134 ACH-001801

[0153] To a solution of compound 26 (80 mg, 155.14 pmol, 1 eq) in Pyridine (1 mL), EDCI (118.96 mg, 620.56 pmol, 4 eq) was added at 0 °C. The mixture was stirred at this temperature for 10 min, and then compound 34 was added (206.65 mg, 465.42 pmol, 3 eq). The mixture was stirred at 25 °C for another 12 h. The reaction mixture was partitioned between water (5 ml) and Ethyl acetate (3 *5 ml). The organic phase was separated, washed with brine (2 * 10 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-HPLC (column: Phenomenex luna C18150*25mm* 10um; mobile phase: [water(FA)-ACN];gradient:15%-45% B over 10 min) to give ACH-001801 (101.79 mg, 106.48 pmol, 68.63% yield, 98.5% purity) as a white solid.

[0154] 1 H-NMR (400 MHz, DMSO-d6) 5 = 9.99 (s, 1 H), 8.62 (d, J = 1.6 Hz, 1 H), 8.36 - 8.29 (m, 1H), 8.18 - 8.15 (m, 1H), 8.02 (dd, J = 2.0, 8.2 Hz, 1H), 7.58 - 7.51 (m, 3H), 7.48 (d, J = 8.8 Hz, 2H), 7.42 (d, J = 2.0 Hz, 1H), 7.31 (td, J = 2.2, 7.6 Hz, 1 H), 7.28 (d, J = 2.2 Hz, 1 H), 7.22 - 7.16 (m, 2H), 7.11 (d, J = 8.4 Hz, 2H), 7.06 (d, J = 8.2 Hz, 1H), 4.32 (t, J = 5.6 Hz, 2H), 3.56 (q, J = 6.4 Hz, 1 H), 2.85 - 2.77 (m, 4H), 2.69 - 2.58 (m, 3H), 2.42 (s, 6H), 2.36 - 2.01 (m, 14H), 1.73 - 1.62 (m, 4H), 1.60 - 1.51 (m, 2H), 1.49 - 1.36 (m, 6H), 1.36 - 1.28 (m, 2H), 1.26 (d, J = 6.8 Hz, 3H)

[0155] LCMS: Rt=0.470 min; [M+H]+=941.5; SFC: Rt = 1.103 min, ee% =95.1%.Preparation of ACH-00180228 ACH-001802

[0156] A mixture of compound 28 (100 mg, 161.61 pmol, 1 eq), compound 35 (26.60 mg, 193.93 pmol, 1.2 eq), AcOH (9.70 mg, 161.61 pmol, 9.25 pL, 1 eq) and NaBHsCN (30.47 mg, 484.82 pmol, 3 eq) in MeOH (1.5 mL) was stirred at 25 °C for 0.5 h. The mixture was quenched with NaHCOs (sat., aq., 20 mL) and extracted with EtOAc (3 * 10 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by Prep-HPLC (column: Phenomenex luna C18 150*25mm* 10um; mobile phase: [water(FA)-ACN];gradient:10%-40% B over 10 min to give ACH- 001802 (25.32 mg, 33.88 pmol, 20.96% yield, 99% purity) as a white solid.

[0157] 1H NMR (400 MHz, DMSO-d6) 5 = 10.04 (s, 1H), 8.62 (d, J = 1.7 Hz, 1H), 8.21 (s, 1H), 8.17 (d, J = 8.3 Hz, 1H), 8.02 (dd, J = 2.1, 8.2 Hz, 1H), 7.59 - 7.49 (m, 4H), 7.43 (d, J = 2.1 Hz, 1 H), 7.36 - 7.28 (m, 5H), 7.27 - 7.19 (m, 3H), 4.66 (t, J = 6.2 Hz, 1H), 4.33 (t, J = 5.9 Hz, 2H), 3.70 (s, 2H), 3.59 - 3.54 (m, 1 H), 2.80 (t, J = 5.9 Hz, 2H), 2.68 - 2.60 (m, 2H), 2.48 - 2.28 (m, 9H), 2.27 - 2.16 (m, 2H), 1.72 - 1.61 (m, 2H), 1.60 - 1.51 (m, 2H), 1.50 - 1.28 (m, 8H), 1.27 (d, J = 6.8 Hz, 3H)

[0158] LCMS: Rt = 0.509 min, m / z = 786.4 [M+H]+Preparation of compound 38""HBoe , JNH36 38

[0159] To a solution of compound 36 (1.00 g, 7.80 mmol, 1.00 eq) and compound 37 (2.59 g, 11.7 mmol, 1.50 eq) in methanol (10.0 mL) was added NaBH3CN (2.45 g, 39.0 mmol, 5.00 eq) and AcOH (2.11 g, 35.1 mmol, 2.01 mL, 4.50 eq). The mixture was stirred at 30 °C for 12 h. The reaction mixture was quenched with water (100 mL) and extracted with ethyl acetate (3 * 30.0 mL). The combined organic layers were washed with brine (2 *40.0 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The crude product was washed with a mixture solution (Petroleum ether: ethyl acetate = 1:1, 50.0 ml) to afford desired Compound 38 (534 mg, 1.44 mmol, 18.47% yield, 90% purity) as a white solid.

[0160] 1 H NMR (400 MHz, DMSO-d6) 5 = 9.27 (s, 1 H), 7.37 (br d, J = 8.2 Hz, 2H), 7.18 (brs, 1H), 7.13 (d, J = 8.4 Hz, 2H), 6.69 (br s, 1H), 3.33 (brs, 2H), 2.76 (br d, J = 11.2 Hz, 2H), 2.08 - 1.99 (m, 1 H), 1.84 (br t, J = 10.6 Hz, 2H), 1.70 - 1.58 (m, 2H), 1.58 - 1.49 (m, 2H), 1.46 (s, 9H)

[0161] LCMS: Rt = 0.404 min, m / z = 334.3 [M+H]+Preparation of compound 3938 39

[0162] Compound 38 (534 mg, 1.60 mmol, 1 eq) was added to HCI / dioxane (10.0 mL). The solution was stirred at 25 °C for 2 h. The reaction mixture was filtered and the cake was washed by Ethyl acetate (10.0 mL) to afford desired product compound 39 (365 mg, 1.15 mmol, 71.81% yield, 85% purity, HCI) as a light yellow solid.

[0163] 1 H NMR (400 MHz, DMSO-d6) 5 = 10.87 (s, 1 H), 7.73 - 7.63 (m, 2H), 7.39 (br d, J = 8.2 Hz, 3H), 7.01 - 6.78 (m, 1 H), 4.37 - 4.18 (m, 3H), 3.40 - 3.26 (m, 2H), 2.88 (br d, J = 0.7 Hz, 2H), 2.37 - 2.26 (m, 1 H), 2.02 (br d, J = 4.0 Hz, 1H), 1.94 - 1.81 (m, 4H).Preparation of ACH-00180339 ACH-001803

[0164] To a solution of compound 26 (80 mg, 155.14 pmol, 1 eq) in Pyridine (1 mL) was added EDCI (118.96 mg, 620.56 pmol, 4 eq) and compound 39 (144.78 mg, 620.56 pmol, 4 eq). The mixture was stirred at 25 °C for 12 h. The reaction mixture was dissolved in water (20 mL) and washed with Ethyl acetate 30 mL (10 mL * 3). After separation, the water phase was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (FA condition; column: Phenomenex luna C18 150*25mm* 10um;mobile phase: [water(FA)-ACN];gradient:6%-36% B over10 min) and prep-HPLC (FA condition; column: Phenomenex luna C18 150*25mm* 10um;mobile phase: [water(FA)-ACN];gradient:6%-36% B over 10 min) to give desired product ACH-001803 (18.82 mg, 25.49 pmol, 16.43% yield, 99% purity) as a yellow solid.

[0165] 1 H NMR (400 MHz, DMSO-d6) 5 = 10.06 (s, 1H), 8.63 (d, J = 1.2 Hz, 1 H), 8.22 - 8.12 (m, 3H), 8.03 (dd, J = 2.0, 8.3 Hz, 1 H), 7.61 - 7.50 (m, 4H), 7.43 (s, 1 H), 7.32 (br d, J = 7.6 Hz, 1 H), 7.21 (d, J = 8.8 Hz, 3H), 6.70 (s, 1 H), 4.33 (br t, J = 5.6 Hz, 2H), 3.62 - 3.57 (m, 1 H), 2.79 (d, J = 6.0 Hz, 4H), 2.49 - 2.17 (m, 11 H), 2.06 - 1.99 (m, 1H), 1.90 (t, J = 10.4 Hz, 2H), 1.73 - 1.34 (m, 16H), 1.27 (br d, J = 6.8 Hz, 3H)

[0166] LCMS: Rt = 0.410 min, 731.4 [M+H]+ ; SFC: Rt = 1.069 min, ee% =94.76%.Preparation of compound 40Intermediate 1 40

[0167] A mixture of compound 27 (56.49 mg, 466.31 pmol, 2 eq), Intermediate 1 (120 mg, 233.16 pmol, 1 eq) and EDCI (178.78 mg, 932.63 pmol, 4 eq) in Pyridine (1.5 mL) was stirred at 0-25 °C for 2 hr. The mixture was added water (10 mL) and extracted with EtOAc (3 * 10 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was triturated with a mixture solution (Petroleum: ethyl acetate = 5: 1, 20 mL). Compound 40 (133 mg, 184.93 pmol, 79.31% yield, 85.9% purity) was obtained as a light yellow solid.

[0168] 1H NMR (400 MHz, CDCI3) 5 = 9.94 (s, 1H), 7.96 (s, 1H), 7.86 (dd, J = 4.8, 8.2 Hz, 2H), 7.74 (d, J = 8.4 Hz, 2H), 7.70 (d, J = 8.4 Hz, 1H), 7.56 (d, J = 7.8 Hz, 1H), 7.51 (s, 1H), 7.48 - 7.39 (m, 3H), 7.11 (dd, J = 2.4, 8.2 Hz, 1H), 6.71 (d, J = 8.4 Hz, 1H), 4.40 (t, J = 5.6 Hz, 2H), 3.40 (q, J = 6.4 Hz, 1H), 2.90 (t, J = 5.6 Hz, 2H), 2.55 (s, 6H), 2.47 - 2.17 (m, 3H), 1.81 (d, J =3.6 Hz, 2H), 1.74 - 1.69 (m, 2H), 1.57 - 1.37 (m, 8H), 1.31 (d, J = 6.4 Hz, 3H). LCMS: Rt = 0.549 min, m / z = 618.4 [M+H]+Preparation of ACH-00179540 ACH-001795

[0169] To a solution of compound 40 (50 mg, 80.93 pmol, 1 eq) and compound 41 (31.12 mg, 242.80 pmol, 3 eq) in DCM (0.5 mL) was added NaBH(OAc)s (102.92 mg, 485.60 pmol, 6 eq) and AcOH (2.43 mg, 40.47 pmol, 2.32 pL, 0.5 eq). The mixture was stirred at 25 °C for 12hr. The reaction mixture was partitioned between water (50 mL) and EtOAc (20 mL). The aqueous layers were washed with EtOAc (20.0 mL * 2). The aqueous phase was basified with NaHCOs (aq. sat.) till PH = 8~9, and then extracted with EtOAc (20 mL * 3). The combined organic layers were washed with brine (30 mL * 2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-HPLC (FA condition; column: Phenomenex luna C18 150*25mm* 10um; mobile phase:[water(FA)-ACN];gradient:9%-39% B over 10 min) to give desired product ACH-001795 (13.18 mg, 17.15 pmol, 21.19% yield, 95% purity) as a white solid.

[0170] 1H NMR (400 MHz, DMSO-d6+H2O-d6) 5 = 8.30 (s, 1H), 7.90 (d, J = 8.4 Hz, 2H), 7.57 - 7.46 (m, 6H), 7.37 (s, 1H), 7.26 (d, J = 8.4 Hz, 2H), 7.24 - 7.15 (m, 1H), 4.28 (t, J = 5.6 Hz, 2H), 3.63 (s, 2H), 3.58 - 3.51 (m, 1H), 3.01 (s, 1H), 2.99 - 2.83 (m, 6H), 2.77 (t, J = 5.6 Hz, 2H), 2.59 (d, J = 6.0 Hz, 4H), 2.42 (d, J = 2.4 Hz, 1H), 2.27 - 2.13 (m, 3H), 1.82 (dd, J = 2.4, 6.4 Hz, 2H), 1.74 - 1.67 (m, 2H), 1.59 (t, J = 10.7 Hz, 4H), 1.52 - 1.31 (m, 8H), 1.23 (d, J = 6.8 Hz, 3H)

[0171] LCMS: Rt = 0.439 min, m / z = 730.4[M+H]+Preparation of ACH-00180428 ACH-001804

[0172] To a solution of compound 42 (78.56 mg, 258.57 pmol, 2 eq) in dichloroethane (0.8 mL) was added DIEA (66.84 mg, 517.14 pmol, 90.08 pL, 4 eq), compound 28 (80.00 mg, 129.29 pmol, 1 eq) and NaBH(OAc)s (68.50 mg, 323.21 pmol, 2.5 eq). The mixture was stirred at 25 °C for 4 h. The reaction mixture was quenched by addition of water (5 mL) at 0 °C and extracted with ethyl acetate (3 mL * 3). The combined organic layers were washed with brine (5 mL *2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-HPLC (column: Phenomenex luna C18 150*25mm* 10um;mobile phase: [water(FA)-ACN];gradient:18%-48% B over 10 min) to give desired product (43 mg, yield 38.2%, purity 85%) as a white solid. After further purification by NPLC (column: Welch Ultimate XB-NH2250*50*10um;mobile phase: [Hexane-EtOH];gradient:15%-55% B over 15 min), desired product ACH-001804 (19 mg, 21.62 pmol, 16.72% yield, 99% purity) was obtained as a white solid.

[0173] 1 H-NMR (400 MHz, DMSO-d6) 5 = 10.04 (s, 1 H), 8.62 (d, J = 1.6 Hz, 1H), 8.17 (d, J = 8.2 Hz, 1H), 8.02 (dd, J = 2.0, 8.2 Hz, 1H), 7.58 - 7.51 (m, 4H), 7.42 (s, 1H), 7.36 - 7.28 (m, 9H), 7.24 - 7.17 (m, 4H), 5.61 (s, 1H), 4.33 (t, J = 5.6 Hz, 2H), 3.64 - 3.52 (m, 1H), 3.36 (s, 2H), 2.79 (t, J = 6.0 Hz, 2H), 2.65 - 2.58 (m, 2H), 2.48 - 2.35 (m, 7H), 2.28 - 2.20 (m, 2H), 2.08 - 1.99 (m, 2H), 1.82 (d, J = 10.4 Hz, 2H), 1.66 (dd, J = 2.2, 7.2 Hz, 2H), 1.61 - 1.52 (m, 4H), 1.47 - 1.37 (m, 6H), 1.36 - 1.30 (m, 2H), 1.27 (d, J = 6.8 Hz, 3H), 1.23 (s, 1H)

[0174] LCMS: Rt = 0.558 min, m / z = 870.5[M+H]+ ; SFC: Rt = 2.151 min, ee% =94.7%.Preparation of ACH-00180528 ACH-001805

[0175] A mixture of compound 28 (115 mg, 185.85 pmol, 1 eq), compound 43 (58.01 mg, 278.77 pmol, 1.5 eq), NaBHsCN (35.04 mg, 557.54 pmol, 3 eq) and DIPEA (72.06 mg, 557.54 pmol, 97.11 pL, 3 eq) in MeOH (2 mL) was stirred at 25 °C for 2 h. The mixture was quenched with NaHCOs (sat., aq., 20 mL) and extracted with EtOAc (3 * 10 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by Prep- HPLC (column: Phenomenex luna C18 150*25mm* 10um;mobile phase: [water(FA)-ACN];gradient:15%-45% B over 10 min) to give desired product ACH-001805 (27.89 mg, 30.04 pmol, 16.16% yield, 98.4% purity) as a white solid.

[0176] 1 H NMR (400 MHz, DMSO-d6) 5 = 10.04 (s, 1 H), 8.62 (d, J = 1.8 Hz, 1H), 8.19 (d, J = 9.2 Hz, 1H), 8.15 (s, 1H), 8.02 (dd, J = 2.0, 8.1 Hz, 1H), 7.58 - 7.52 (m, 4H), 7.43 (d, J = 2.0 Hz, 1 H), 7.37 (s, 1 H), 7.33 - 7.26 (m, 4H), 7.23 (d, J = 8.4 Hz, 2H), 4.68 (dd, J = 4.7, 7.5 Hz, 1H), 4.33 (t, J = 5.8 Hz, 2H), 3.70 (d, J = 1.5 Hz, 2H), 3.56 (d, J = 6.7 Hz, 1H), 2.80 (t, J = 5.8 Hz, 2H), 2.69 - 2.58 (m, 2H), 2.46 - 2.32 (m, 8H), 2.24 (br d, J = 3.3 Hz, 2H), 1.69 - 1.61 (m, 2H), 1.57 (dt, J = 4.1 , 6.5 Hz, 2H), 1.51 - 1.31 (m, 8H), 1.26 (d, J = 6.7 Hz, 3H)

[0177] LCMS: Rt = 0.517 min, m / z = 774.3[M+H]+Preparation of ACH-00180628 ACH-001806

[0178] To a solution of compound 28 (72 mg, 116.36 pmol, 1 eq) in DCM (0.500 mL) was added DIEA (60.2 mg, 465 pmol, 81.1 pL, 4.00 eq), compound 44 (63.62 mg, 233 pmol, 2.00 eq) and NaBH(OAc)s (49.3 mg, 233 pmol, 2.00 eq). The mixture was stirred at 25 °C for 12 h. The reaction mixture was quenched with water (50.0 mL) and extracted with ethyl acetate (3 * 40.0 mL). The combined organic layers were washed with brine 100 mL (2 * 50 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-HPLC (FA condition;column: Phenomenex luna C18 150*25mm* 10um;mobile phase:[water(FA)-ACN];gradient:9%-39% B over 10 min ) and Prep-HPLC (FA condition;column: Phenomenex luna C18 150*25mm* 10um;mobile phase:[water(FA)-ACN];gradient:11 %-41 % B over 10 min) to give desired compound (35 mg, yield 34 %, purity 93%) as a white solid. After further purification by NPLC (column: Welch Ultimate XB-SiOH250*50*10um;mobile phase: [Hexane-EtOH];gradient:5%-45% B over 15 min), desired product ACH-001806 (15.18 mg, 17.15 pmol, 14.74% yield, 99% purity) was obtained as a white solid.

[0179] 1 H NMR (400 MHz, DMSO-d6) 5 = 10.07 (s, 1 H), 8.62 (d, J = 1.6 Hz, 1H), 8.17 (d, J = 8.0 Hz, 1H), 8.02 (dd, J = 2.0, 8.1 Hz, 1H), 7.61 - 7.48 (m, 6H), 7.43 (s, 1H), 7.32 (td, J = 2.0, 7.3 Hz, 1H), 7.25 (d, J = 8.4 Hz, 2H), 7.19 - 7.10 (m, 2H), 4.46 - 4.26 (m, 4H), 3.59 - 3.59 (m, 1 H), 3.63 (t, J = 5.2 Hz, 1 H), 3.55 (q, J = 6.8 Hz, 1 H), 3.46 (s, 2H), 3.33 - 3.27 (m, 3H), 3.09 - 2.96 (m, 1 H), 2.91 (br d, J = 11.2 Hz, 2H), 2.81 (br t, J = 5.6 Hz, 2H), 2.39 (br s, 6H), 2.27 - 2.17 (m, 2H), 2.06 (dt, J = 2.8, 11.2 Hz, 2H), 1.96 - 1.79 (m, 4H), 1.71 - 1.61 (m, 2H), 1.60 - 1.50 (m, 2H), 1.50 - 1.36 (m, 6H), 1.35 - 1.28 (m, 2H), 1.26 (d, J = 6.8 Hz, 3H), 0.98 (t, J = 7.2 Hz, 3H)

[0180] LCMS: Rt = 0.431 min, 876.6[M+H]+ ; SFC: Rt = 1.108 min, ee% =93.054%.Preparation of ACH-001 79640 ACH-001796

[0181] A mixture of compound 40 (60 mg, 97.12 pmol, 1 eq), compound 45 (60.18 mg, 194.24 pmol, 2 eq), DIEA (62.76 mg, 485.60 pmol, 84.58 pL, 5 eq) and NaBH(OAc)s (61.75 mg, 291.36 pmol, 3 eq) in DCM (1 mL) was stirred at 0-25 °C for 12 h. The mixture was quenched with water (20 mL) at 0 °C, then the resultant mixture was extracted with EtOAc (3 * 10 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by Prep-HPLC (column: Phenomenex luna C18 150*25mm* 10um;mobile phase: [water(FA)-ACN];gradient:12%-42% B over 10 min). ACH-001796 (27.82 mg, 31.79 pmol, 99.99% purity) was obtained as a yellow solid.

[0182] LCMS: Rt = 0.525 min, m / z = 875.5 [M+H]+

[0183] 1 H NMR (400 MHz, DMSO-d6+D2O) 5 = 7.89 (d, J = 8.4 Hz, 2H), 7.59 - 7.46 (m, 8H), 7.40 (s, 1H), 7.32 - 7.22 (m, 3H), 7.20 - 7.11 (m, 2H), 4.56 - 4.25 (m, 4H), 3.62 (t, J = 4.8 Hz, 2H), 3.48 (s, 2H), 3.45 - 3.38 (m, 1H), 3.30 (q, J = 6.8 Hz, 2H), 3.07 - 2.96 (m, 1 H), 2.90 (d, J = 11.2 Hz, 2H), 2.78 (t, J = 5.8 Hz, 2H), 2.47 (s, 6H), 2.42 -2.35 (m, 1H), 2.28 - 2.16 (m, 2H), 2.13 - 2.02 (m, 2H), 1.95 - 1.76 (m, 4H), 1.73 - 1.62 (m, 2H), 1.55 ( dd, J = 3.2, 8.2 Hz, 2H), 1.48 - 1.26 (m, 8H), 1.21 (d, J = 6.4 Hz, 3H), 0.95 (t, J = 7.2 Hz, 3H).Preparation of compound 48>>46 48

[0184] Compound 46 (800 mg, 3.07 mmol, 1 eq), compound 47 (860 mg, 3.63 mmol, 1.18 eq) and K2CO3 (1.27 g, 9.21 mmol, 3 eq) were taken up into a microwave tube in ACN (4 mL). The sealed tube was heated at 165 °C for 2hr under microwave. After cooling to 25 °C, ethyl acetate (30 mL) andwater (30 mL) were added. The aqueous phase was extracted with ethyl acetate (20 mL * 3). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na2SO4, concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0~56% Ethyl acetate / Petroleum ethergradient at 20 mL / min). Compound 48 (220 mg, 466.42 pmol, 15.20% yield, 90% purity) was obtained as a white solid.

[0185] 1 H NMR (400 MHz, CHLOROFORM-d) 5 = 7.54 (d, J = 7.8 Hz, 1 H), 7.19 - 7.10 (m, 3H), 7.09 - 7.01 (m, 4H), 5.07 (s, 2H), 4.16 - 4.05 (m, 1H), 4.03 - 3.81 (m, 2H), 3.73 (d, J = 7.7 Hz, 1H), 2.95 (t, J = 12.0 Hz, 2H), 2.15 -2.00 (m, 2H), 1.46 (s, 9H), 1.30 - 1.21 (m, 2H).

[0186] LCMS: Rt = 0.563 min, m / z = 425.3 [M+H]+Preparation of compound 49""48 49

[0187] To a solution of tert-butyl 4-[[1-[(4-fluorophenyl)methyl]benzimidazol-2- yl]amino]piperidine-1 -carboxylate (compound 48) (100 mg, 235.57 pmol, 1 eq) in DCM (1 mL) was added TFA (460.50 mg, 4.04 mmol, 0.3 mL, 17.14 eq). The mixture was stirred at 25 °C for 1 hr. The reaction mixture was concentrated under reduced pressure to remove solvent. The crude product compound 49 (100 mg, 216.69 pmol, 91.99% yield, 95% purity, TFA) was obtained as yellow oil. LCMS: Rt = 0.410 min, m / z = 325.2[M+H]+ Preparation of ACH-00179749 ACH-001797

[0188] To a solution of compound 49 (86.50 mg, 197.30 pmol, 2.22 eq, TFA) in DCM (0.5 mL) was added DIEA (45.95 mg, 355.54 pmol, 61.93 pL, 4 eq), compound 50 (55 mg, 88.88 pmol, 1 eq) and NaBH(OAc)s (60 mg, 283.10 pmol, 3.19 eq). The mixture was stirred at 25 °C for 12hr. The mixture was poured into water (20 mL) and extracted with EtOAc (10 mL * 3). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by Prep-TLC (DCM: MeOH = 10:1, UV) to give a crude, which was further purified by Prep-HPLC (column: Phenomenex luna C18 150*25mm* 10um;mobile phase: [water(FA)-ACN];gradient:9%-39% B over 10 min) to give ACH-001797 (19.6 mg, 20.72 pmol, 23.31% yield, 98% purity) as a white solid.

[0189] 1 H NMR (400 MHz, DMSO-d6+D2O) 5 = 8.58 (s, 1 H), 8.32 (s, 1 H), 8.15 (d, J = 8.1 Hz, 1 H), 8.01 (dd, J = 1.6, 8.4 Hz, 1 H), 7.59 - 7.45 (m, 4H), 7.38 (s, 1H), 7.25 (d, J = 8.4 Hz, 3H), 7.20 (d, J = 7.6 Hz, 1H), 7.17 - 7.10 (m, 2H), 7.10 - 6.99 (m, 3H), 6.95 (t, J = 7.6 Hz, 1H), 6.90 -6.83 (m, 1H), 5.17 (s, 2H), 4.28 (t, J = 5.6 Hz, 2H), 3.72 (t, J = 10.4 Hz, 1H), 3.63 (q, J = 6.4 Hz, 1H), 3.53 (s, 2H), 3.14 (s, 1H), 2.98 - 2.62 (m, 10H), 2.48 - 2.33 (m, 3H), 2.26 (s, 2H), 1.99 - 1.87 (m, 2H), 1.76 (d, J = 8.0 Hz, 2H), 1.55 (d, J = 10.4 Hz, 4H), 1.46 - 1.27 (m, 8H), 1.24 (d, J = 6.8 Hz, 3H). LCMS: Rt = 1.75 min, m / z = 927.5[M+H]+Preparation of compound 5351 53

[0190] Compound 51 (2 g, 13.11 mmol, 1 eq), Compound 52 (2.63 g, 13.11 mmol, 2.58 mL, 1 eq) and TEA (2.65 g, 26.22 mmol, 3.65 mL, 2 eq) were taken up into a microwave tube in DMF (5 mL). The sealed tube was heated at 175 °C for 0.5 h under microwave. The reaction mixture was poured into water (100 mL) and extracted with EtOAc (50 mL * 3). The combinedorganic layers were washed with brine (60 mL * 2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0~100% Ethyl acetate / Petroleum ethergradient at 50 mL / min). Compound 53 (2.566 g, 6.81 mmol, 51.97% yield, 84% purity) was obtained as a white solid.

[0191] 1H NMR (400 MHz, DMSO-d6) 5 = 11.15 (d, J = 2.0 Hz, 1H), 7.13 (dd, J = 7.6, 12.1 Hz, 2H), 6.93 - 6.88 (m, 1 H), 6.86 - 6.81 (m, 1 H), 3.72 - 3.46 (m, 6H), 3.31 - 3.17 (m, 2H), 1.97 - 1.71 (m, 2H), 1.33 - 1.23 (m, 9H)

[0192] LCMS: Rt = 0.424 min, m / z = 317.2[M+H]+Preparation of compound 5554 55

[0193] To a solution of compound 54 (2 g, 22.19 mmol, 2.15 mL, 1 eq) and TosCI (3.81 g, 19.97 mmol, 0.9 eq) in DCM (20 mL) was added TEA (4.49 g, 44.38 mmol, 6.18 mL, 2 eq). The mixture was stirred at 25 °C for 12 hr. The reaction mixture was poured into water (100 mL) and extracted with EtOAc (50 mL * 3). The combined organic layers were washed with brine (60 mL * 2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 20 g SepaFlash® Silica Flash Column, Eluent of 0~25% Ethyl acetate / Petroleum ethergradient at 40 mL / min). Compound 55 (2.4 g, 9.33 mmol, 42.05% yield, 95% purity) was obtained as a colorless oil.

[0194] 1 H NMR (400 MHz, CHLOROFORM-d) 5 = 7.27 (s, 2H), 6.82 (d, J = 8.0 Hz, 2H), 3.67 - 3.59 (m, 2H), 3.27 - 3.07 (m, 2H), 2.93 (q, J = 7.2 Hz, 2H), 1.92 (s, 3H), 0.61 (t, J = 7.2 Hz, 3H)Preparation of compound 56 >"53 56

[0195] To an ice-cooled solution of compound 53 (1 g, 3.16 mmol, 1 eq) in DMF (10 mL) under argon was added NaH (189.64 mg, 4.74 mmol, 60% purity, 1.5 eq). After stirring for 20 min, a solution of compound 55 (1.16 g, 4.74 mmol, 1.5 eq) in DMF (10 mL) was added. The mixture was stirred at 40 °C for another 12h. The reaction mixture was quenched by addition of NH4CI (sat., aq., 20 mL) at 0 °C, and then diluted with water (50 mL) and extracted with EtOAc (30 mL * 3). The combined organic layers were washed with brine (40 mL * 2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 20 g SepaFlash® Silica Flash Column, Eluent of 0~100% Ethyl acetate / Petroleum ethergradient at 20 mL / min). Compound 56 (0.9 g, 2.20 mmol, 69.63% yield, 95% purity) was obtained as a white solid. LCMS: Rt = 0.535 min, m / z = 389.3[M+H]+

[0196] 1 H NMR (400 MHz, CHLOROFORM-d) 5 = 7.60 - 7.52 (m, 1 H), 7.29 (d, J = 7.8 Hz, 1H), 7.23 - 7.12 (m, 2H), 4.20 (t, J = 5.9 Hz, 2H), 3.81 (t, J = 5.9 Hz, 2H), 3.73 - 3.64 (m, 2H), 3.62 - 3.51 (m, 5H), 3.47 (q, J = 6.8 Hz, 3H), 2.05 - 1.91 (m, 2H), 1.49 (d, J = 3.8 Hz, 9H), 1.15 (t, J = 6.9 Hz, 3H).Preparation of compound 57

[0197] To a solution of compound 56 (380mg, 978.11 umol, 1 eq) in DCM (6 mL) was added TFA (2.33 g, 20.46 mmol, 1.52 mL, 20.92 eq). The mixture was stirred at 25 °C for 1h. The reaction mixture was concentrated under reduced pressure to give a residue. The crude product 57 (282 mg, 977.85pmol, 99.97% yield) was obtained as yellow oil. LCMS: Rt = 0.379 min, m / z = 289.2[M+H]+Preparation of ACH-00179857 ACH-001798

[0198] To a solution of compound 57 (97.55 mg, 242.41 pmol, 3 eq, TFA) and compound 50 (50 mg, 80.80 pmol, 1 eq) in DCM (1 mL) was added DIEA (41.77 mg, 323.21 pmol, 4 eq) and NaBH(OAc)3(51.38 mg, 242.41 pmol, 3 eq). The mixture was stirred at 25 °C for 12hr. The reaction mixture was diluted with water (100 mL) and extracted with EtOAc (50 mL * 3). The combined organic layers were washed with brine (50 mL * 2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-TLC (SiO2, DCM: MeOH = 10 : 1). The residue was purified by Prep-HPLC (FA condition; column:Phenomenex luna C18 150*25mm* 10um; mobile phase: [water(FA)-ACN]; gradient:8%-38% B over 10 min). Compound ACH-001798 (21.8 mg, 23.97 pmol, 29.67% yield, 98% purity) was obtained as a white solid. LCMS: Rt = 1.667 min, m / z = 891 ,5[M+H]+

[0199] 1H NMR (400 MHz, DMSO-d6) 5 = 10.06 (s, 1H), 8.62 (s, 1H), 8.17 (d, J = 8.4 Hz, 1 H), 8.02 (d, J = 8.4 Hz, 1 H), 7.60 - 7.48 (m, 4H), 7.43 (s, 1 H), 7.37 - 7.24 (m, 5H), 7.11 - 6.92 (m, 2H), 4.33 (t, J = 5.6 Hz, 2H), 4.17 (t, J = 5.6 Hz, 2H), 3.72 (t, J = 5.6 Hz, 2H), 3.62 - 3.53 (m, 7H), 3.39 (s, 2H), 2.84 - 2.73 (m, 4H), 2.71 - 2.63 (m, 2H), 2.59 - 2.55 (m, 1 H), 2.45 (s, 5H), 2.39 - 2.34 (m, 1H), 2.31 - 2.17 (m, 2H), 1.91 (s, 2H), 1.71 - 1.62 (m, 2H), 1.61 - 1.53 (m, 2H), 1.51 - 1.29 (m, 8H), 1.26 (d, J = 6.8 Hz, 3H), 1.00 (t, J = 6.8 Hz, 3H)Preparation of compound 5958 59

[0200] Compound 58 (200 mg, 740.90 pmol, 1 eq) was introduced in portions at 0 °C into NaOH (aq., 1 M, 12.00 mL, 16.20 eq) solution. The resulting solution was acidified to pH = 3 with 1 N HCI solution and stirred for 1 hour. The mixture was cooled, and the resulting precipitate was filtered off and washed with a mixture solution of water / ACN (3: 1, 10 mL) and ACN (2 mL * 2) to afford compound 59 (135 mg, 521.90 pmol, 70.44% yield, 76% purity) as a brown solid.

[0201] 1 H NMR (400 MHz, DMSO-d6) 5 =7.70 (d, J = 2.0 Hz, 1 H), 7.68 - 7.65 (m, 1 H), 7.36 (dd, J = 2.0, 8.6 Hz, 1 H). LCMS: Rt = 0.342 min, m / z = 196.9 [M+H]+Preparation of compound 60><59 60

[0202] To a solution of compound 7 (153.48 mg, 824.05 pmol, 1.2 eq) in DCM (2 mL) was added DIEA (266.26 mg, 2.06 mmol, 358.83 pL, 3 eq), HATU (287.22 mg, 755.38 pmol, 1.1 eq) and compound 59 (135 mg, 686.71 pmol, 1 eq). The mixture was stirred at 25 °C for 12 hr. The reaction mixture was partitioned between water (10 mL) and DCM (20 mL). The organic phase was separated, washed with brine (10 mL * 3), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0~37% Ethyl acetate / Petroleum ethergradient at 20 mL / min). Compound 60 (132 mg, 354.58 pmol, 51.63% yield, 98% purity) was obtained as a yellow solid.

[0203] 1 H NMR (400 MHz, CDCI3) 6 = 11.13 - 10.33 (m, 1H), 8.01 - 7.40 (m, 2H), 7.33 (d, J = 7.8 Hz, 1 H), 4.81 - 4.69 (m, 2H), 3.92 - 3.76 (m, 2H), 3.61 (td, J = 5.3, 11.2 Hz, 4H), 1.51 (s, 9H), 1.31 - 1.31 (m, 1 H)

[0204] LCMS: Rt = 0.562 min, 365.2[M+H]+Preparation of compound 61"

[0205] To a solution of compound 60 (110 mg, 301.51 pmol, 1 eq) in DCM (1 mL) was added TFA (460.50 mg, 4.04 mmol, 0.3 mL, 13.39 eq). The mixture was stirred at 25 °C for 1 h. The reaction mixture was concentrated under reduced pressure to give crude product compound 61 (114 mg, crude, TFA) as a light yellow solid. LCMS: Rt = 0.411 min, m / z = 265.2 [M+H]+ Preparation of ACH-00179961 ACH-001799

[0206] To a solution of compound 61 (110.17 mg, 290.89 pmol, 4 eq, TFA) in DCM (1 mL) was added DIEA (37.60 mg, 290.89 pmol, 50.67 pL, 4 eq), compound 50 (45 mg, 72.72 pmol, 1 eq) and sodium triacetoxyboranuide (38.53 mg, 181.81 pmol, 2.5 eq). The mixture was stirred at 25 °C for 12 h. The reaction mixture was partitioned between water (10 ml) and DCM (15 mL). The organic phase was separated, washed with brine (10 mL * 2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-TLC (SiO2, DCM: MeOH = 10:1) to give desired product ACH-001799 (100 mg, yield 79%, purity 50%) as a white solid. After further purification by Prep-NPLC (column:Welch Ultimate XB-SiOH 250*50*10um;mobile phase: [Hexane-EtOH(0.1% NH3.H2O) ];gradient: 1 %-40% B over 15 min), ACH-001799 (15.29 mg, 17.27 pmol, 23.75% yield, 98% purity) was obtained as a white solid.

[0207] 1H NMR (400 MHz, DMSO-d6+D2O) 5 = 8.58 (s, 1H), 8.14 (d, J = 8.2 Hz, 1 H), 8.00 (d, J = 7.8 Hz, 1 H), 7.71 - 7.60 (m, 2H), 7.58 - 7.49 (m, 4H), 7.39 (s, 1H), 7.29 (d, J = 8.2 Hz, 2H), 7.23 (d, J = 8.2 Hz, 2H), 4.30 (d, J = 4.8 Hz, 4H), 3.80 (d, J = 6.4 Hz, 2H), 3.52 (d, J = 6.8 Hz, 1H), 3.45 (s, 2H), 2.78 (t, J = 5.0 Hz, 2H), 2.43 (d, J = 2.4 Hz, 4H), 2.36 (s, 7H), 2.24 - 2.14 (m, 2H), 1.61 (d, J = 8.4 Hz, 2H), 1.56 - 1.47 (m, 2H), 1.46 - 1.26 (m, 8H), 1.23 (d, J = 6.4 Hz, 4H)

[0208] LCMS: Rt = 0.454 min, m / z = 867.5 [M+H]+Preparation of compound 63"62 63

[0209] To a solution of compound 62 (2.00 g, 10.9 mmol, 1.00 eq) and ethylene glycol (3.37 g, 54.3 mmol, 3.03 mL, 5.00 eq) in toluene (20.0 mL) was added H2SO4 (1.06 g, 10.86 mmol, 578.65 pL, 1 eq). The mixture was stirred at 90 °C for 2 h. The reaction mixture was quenched by addition of NaHCOs (aq. sat., 10 mL) at 0 °C, and then diluted with water (200 mL) and extracted with EtOAc (60 mL * 3). The combined organic layers were washed with brine (100 mL *2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0~30% Ethyl acetate / Petroleum ethergradient at 50 mL / min) to give compound 63 (2 g, 8.76 mmol, 80.70% yield) obtained as a white solid.Preparation of compound 64" " "" "" "63 64

[0210] To a solution of compound 63 (500 mg, 2.19 mmol, 1 eq) and DPPA (1.02 g, 3.72 mmol, 804 pL, 1.70 eq) in THF (5.00 mL) was added PPh3(862 mg, 3.29 mmol, 1.50 eq) and DIAD (752.90 mg, 3.72 mmol, 722 pL, 1.70 eq). The mixture was stirred at 25 °C for 12 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0~20% Ethyl acetate / Petroleum ether gradient at 30 mL / min) to give compound 64 (269 mg, 1.06 mmol, 49% yield) as a white solid.Preparation of compound 65<64 65

[0211] To a solution of compound 64 (269 mg, 1.06 mmol, 1 eq) in THF (2.70 mL) was added PPh3(334 mg, 1.27 mmol, 1.20 eq) and H2O (0.300 mL). The mixture was stirred at 25 °C for 12 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by Prep-HPLC (FA condition; column: Phenomenex luna C18 150*40mm* 15um;mobile phase: [water(FA)-ACN];gradient:16%-46% B over 10 min ) to give compound 65 (201 mg, 875 pmol, 82% yield, 99% purity) as a white solid.

[0212] 1 H NMR (400 MHz, DMSO-d6) 5 = 8.38 (s, 1 H), 7.45 - 7.39 (m, 4H), 7.33 (t, J = 7.6 Hz, 4H), 7.27 - 7.21 (m, 2H), 5.48 (s, 1H), 3.47 (t, J = 5.6 Hz, 2H), 2.91 (t, J = 5.6 Hz, 2H).

[0213] LCMS: Rt = 0.455 min, 167.2[M+H]+Preparation of ACH-00180765 ACH-001807

[0214] To a solution of compound 65 (36.73 mg, 162 pmol, 2.00 eq) and compound 28 (50 mg, 80.8 pmol, 1.00 eq) in dichloromethane (0.500 mL) was added NaBH(OAc)s (51.4 mg, 242 pmol, 3.00 eq). The mixture was stirred at 25 °C for 4 h. The reaction mixture was quenched with water (50.0 mL) and extracted with ethyl acetate (3 * 40.0 mL). The combined organic layers were washed with brine (2 * 50.0 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-HPLC (FA condition; column: Phenomenex luna C18 150*25mm* 10um;mobile phase: [water(FA)-ACN];gradient:17%- 47% B over 10 min) to give desired product ACH-001807 (16.3 mg, 19.44 pmol, 24.06% yield, 99% purity) as a white solid.

[0215] 1 H NMR (400 MHz, DMSO-d6) 5 = 10.07 (s, 1 H), 8.62 (s, 1 H), 8.26 (s, 1H), 8.17 (d, J = 8.0 Hz, 1H), 8.02 (d, J = 7.2 Hz, 1H), 7.60 - 7.48 (m, 4H), 7.43 (br s, 1H), 7.41 - 7.28 (m, 10H), 7.27 - 7.20 (m, 4H), 5.44 (s, 1H), 4.33 (br s, 3H), 3.70 (s, 2H), 3.56 - 3.55 (m, 1 H), 3.48 (br s, 2H), 2.80 (br t, J = 5.6 Hz, 2H), 2.75 (t, J = 5.2 Hz, 2H), 2.41 (s, 5H), 2.27 - 2.18 (m, 2H), 1.71 - 1.62 (m, 2H), 1.61 - 1.52 (m, 2H), 1.48 - 1.30 (m, 8H), 1.27 - 1.22 (m, 3H). LCMS: Rt = 0.4671 min, 830.5[M+H]+ ; SFC: Rt = 1.010 min, ee% = 99.99%.Preparation of compound 6866 68

[0216] To a solution of compound 66 (1.162 g, 8.06 mmol, 2.91 mL, 1 eq) in / V, / V-dimethylfonriamide (20 mL) was added NaH (419.08 mg, 10.48 mmol, 60% purity, 1.3 eq) at 0 °C under nitrogen atmosphere. The mixture wasstirred at 0 °C for 0.5 h under nitrogen atmosphere, and then compound 67 (3.13 g, 12.09 mmol, 1.5 eq) was added. The resultant mixture was stirred at 20 °C for 1 h. The reaction mixture was quenched by addition NH4CI (sat., aq., 5 mL) at 0 °C, and then diluted with water (5 mL) and extracted with Ethyl acetate (5 mL * 3). The combined organic layers were washed with brine (10 mL *2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 20 g SepaFlash® Silica Flash Column, Eluent of 0~10% Ethyl acetate / Petroleum ethergradient at 60 mL / min). Compound 68 (1.52 g, 7.21 mmol, 89.47% yield, 95% purity) was obtained as a colorless oil.

[0217] 1 H-NMR (400 MHz, CDCI3) 5 = 8.38 - 8.27 (m, 1 H), 7.86 - 7.78 (m, 1 H), 7.56 - 7.44 (m, 3H), 7.42 - 7.34 (m, 1 H), 6.83 (d, J = 7.6 Hz, 1 H), 4.42 (dd, J = 3.2, 11.2 Hz, 1H), 4.17 (dd, J = 5.6, 11.2 Hz, 1H), 3.51 (tdd, J = 2.8, 4.0, 5.6 Hz, 1H), 2.99 (t, J = 4.4 Hz, 1H), 2.87 (dd, J = 2.6, 4.8 Hz, 1H); SFC: Rt = 0.876 min, ee% > 99.9%.Preparation of compound 7068 70

[0218] To a solution of compound 68 (300 mg, 1.50 mmol, 1 eq) in Propan-2-ol (3 mL) was added compound 69 (250.76 mg, 1.65 mmol, 1.1 eq). The mixture was stirred at 25 °C for 12 h. Methanol (3 mL), BOC2O (616.87 mg, 2.83 mmol, 649.33 pL, 2 eq) and TEA (143.01 mg, 1.41 mmol, 196.71 pL, 1 eq) was added. The mixture was stirred at 25 °C for 1 h. The reaction mixture was concentrated under reduced pressure to remove Methanol and Propan-2-ol. The residue was diluted with water (20 mL) and extracted with Ethyl acetate (10 mL * 3). The combined organic layers were washed with brine (30 mL * 2), dried over anhydrous Na2SO4, filtered and concentratedunder reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0~21% Ethyl acetate / Petroleum ethergradient at 30 mL / min).Compound 70 (273 mg, 567.12 pmol, 40.13% yield, 94% purity) as a white solid. 1H-NMR (400 MHz, CDCI3) 5 = 8.13 (d, J = 8.0 Hz, 3H), 7.83 (d, J = 8.0 Hz, 1H), 7.56 - 7.42 (m, 3H), 7.41 - 7.28 (m, 3H), 6.81 (d, J = 7.4 Hz, 1 H), 4.82 - 4.43 (m, 2H), 4.39 - 4.31 (m, 1 H), 4.24 - 4.16 (m, 1 H), 4.09 (s, 1 H), 3.72 - 3.47 (m, 2H), 1.57 - 1.50 (m, 3H), 1.46 (s, 6H) Preparation of compound 7170 71

[0219] To a solution of compound 70 (273 mg, 603.32 pmol, 1 eq) in Ethyl acetate (10 mL) was added Pd / C (1 g, 10% purity) under nitrogen. The suspension was degassed under vacuum and purged with hydrogen several times. The mixture was stirred under hydrogen (15 Psi) at 25 °C for 12 h. The reaction mixture was filtered and concentrated under reduced. The residue was purified by Prep-HPLC (column: Phenomenex luna C18 150*25mm* 10um; mobile phase: [water(FA)-ACN];gradient:34%-64% B over 10 min). Compound 71 (111 mg, 257.46 pmol, 42.67% yield, 98% purity) was obtained as a white solid.

[0220] 1 H-NMR (400 MHz, CDCI3) 5 = 8.22 - 8.14 (m, 1 H), 7.85 - 7.79 (m, 1 H), 7.53 - 7.44 (m, 3H), 7.40 - 7.35 (m, 1 H), 7.20 - 6.99 (m, 3H), 6.85 - 6.77 (m, 1 H), 6.73 - 6.64 (m, 2H), 4.46 (br d, J = 14.5 Hz, 2H), 4.29 (br dd, J = 5.3, 10.9 Hz, 2H), 4.13 (q, J = 7.1 Hz, 2H), 1.52 (s, 11 H)Preparation of compound 7271 72

[0221] To a solution of compound 26 (80 mg, 155.14 pmol, 1 eq) in Pyridine (1 mL), EDCI (118.96 mg, 620.56 pmol, 4 eq) was added at 0 °C. The mixture was stirred at 0 °C for 0.5 h, and then compound 71 (98.32 mg, 232.71 pmol, 1.5 eq) was added. The mixture was stirred at 25 °C for another 1 h. The reaction mixture was partitioned between water (5 mL) and ethyl acetate (5 mL). The organic phase was separated, washed with brine (5 mL * 2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-HPLC (column: Phenomenex Luna C18 150*25mm*10um; mobile phase:[water(FA)-ACN];gradient:33%-63% B over 10 min). Compound 72 (72 mg, 75.90 pmol, 48.92% yield, 97% purity) was obtained as a white solid.

[0222] 1H-NMR (400 MHz, DMSO-d6) 5 = 10.10 - 10.04 (m, 1H), 8.61 (d, J = 1.6 Hz, 1 H), 8.21 - 8.14 (m, 3H), 8.01 (dd, J = 2.2, 8.2 Hz, 1 H), 7.88 - 7.81 (m, 1H), 7.58 - 7.36 (m, 9H), 7.31 (td, J = 2.2, 7.2 Hz, 1H), 7.16 (br d, J = 7.6 Hz, 2H), 6.89 (d, J = 7.2 Hz, 1 H), 5.35 - 5.25 (m, 1 H), 4.47 - 4.40 (m, 1 H), 4.38 - 4.30 (m, 2H), 4.26 - 4.15 (m, 1 H), 4.07 - 3.99 (m, 2H), 3.60 - 3.42 (m, 2H), 2.84 - 2.76 (m, 2H), 2.41 (s, 6H), 2.27 - 2.17 (m, 2H), 1.70 - 1.61 (m, 2H), 1.61 - 1.52 (m, 2H), 1.49 - 1.29 (m, 18H), 1.26 (d, J = 6.8 Hz, 3H).LCMS: Rt = 0.568 min, 920.6[M+H]+Preparation of ACH-00180872 ACH-001808

[0223] To a solution of compound 72 (60 mg, 65.21 pmol, 1 eq) in Ethyl acetate (0.5 mL) was added HCI / dioxane (2 M, 0.5 mL). The mixture was stirred at 25 °C for 1 h. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was diluted with water (5 mL) and extracted with Ethyl acetate (5 mL * 3). The combined organic layers were washed with brine (10 mL *2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-HPLC (column: Phenomenex luna C18 150*25mm* 10um; mobile phase: [water(HCI)-ACN];gradient:21%-51% B over 9 min) to give the desired product ACH-001808 (38.93 mg, 45.00 pmol, 69.01% yield, 99% purity, HCI) as a white solid.

[0224] 1 H-NMR (400 MHz, DMSO-d6) 5 = 10.37 (s, 1 H), 9.51 - 9.28 (m, 1 H), 9.27 - 8.99 (m, 1 H), 8.97 - 8.75 (m, 1 H), 8.48 - 8.18 (m, 2H), 8.17 - 8.05 (m, 1 H), 7.92 - 7.80 (m, 1 H), 7.69 (d, J = 8.4 Hz, 2H), 7.59 - 7.45 (m, 8H), 7.43 - 7.38 (m, 1 H), 7.36 - 7.29 (m, 1 H), 6.95 (d, J = 7.6 Hz, 1 H), 4.52 - 4.27 (m, 4H), 4.21 - 4.09 (m, 4H), 3.55 - 3.26 (m, 7H), 3.26 - 3.17 (m, 2H), 3.11 - 2.99 (m, 2H), 2.87 (t, J = 5.8 Hz, 2H), 2.07 - 1.98 (m, 2H), 1.70 - 1.39 (m, 13H). LCMS: Rt = 0.457 min, 820.5[M+H]+ ; SFC: Rt = 1.164 min, ee% =94.1%.

[0225] [Table 1], Preferred compounds according to the present invention<<>Example 1 - Pharmacological testing

[0226] The practice of the current invention for the treatment of diseases by modulation of muscarinic receptor M3 and / or the histamine receptor H1 can be evidenced by the activity in at least one of the protocols described herein.

[0227] In vitro human muscarinic M3 receptor (hM3) binding assay

[0228] Affinity for the human muscarinic M3 receptor was determined by measuring ability of the test compounds to displace the binding of N-methyl- [3H] scopolamine ([3H]-NMS) to cell membrane preparations expressing the receptor. Test compounds were added to the assay plate from a DMSO stock solution in a 10-point 3-fold serial dilution with 100 nM - 100 pM as the maximum concentration. Membrane (1.25 pg / well) and [3H]-NMS (0.6 nM) were added to the assay plate. Buffer was HEPES (10 mM, pH 7.4) supplemented with MgCI2 (1 mM). Atropine (1 pM / well) was included into specific wells to account for nonspecific binding and DMSO for total binding. Plates were sealed and shaken at 300 rpm at room temperature for 24 h (incubation time). Unifilter-96 GF / B filter plates were washed to remove the excess free ligand from the bound receptor-ligand complex using Perkin Elmer Filtermate Harvester. Plates were dried for 1 hour at 50°C. Microscint 20 cocktail (PerkinElmer, Cat. # 6013329) was added and remaining radioligand was evaluated using TopCount NXT HTS Reader (PerkinElmer). Half maximal inhibitory concentrations (IC50) were calculated using GraphPad Prism 5 (GraphPad Software Inc., USA). The inhibition constants (Ki) were calculated using the Cheng-Prusoff equation. Experiments were performed in duplicate.

[0229] In vitro human muscarinic M3 receptor (hM3) functional antagonismassay

[0230] Antagonism of human muscarinic M3 receptor was assessed using stable CHO-K1 cell lines expressing the hM3 receptor. Cells (2x104 / well) were added to the plates and incubated overnight at 37 °C and 5% CO2. Fluo-4 DirectTM (Life Technologies, Cat. # F10471), a fluorescent Ca2+indicator, was added at the final concentration of 4 pM. Test compounds were added to the plates and pre-incubated with cells for 1 hour (for 50 minutes at 37 °C and 5% CO2 and then for 10 min at room temperature). Afterwards, plates were transferred to FLIPR Tetra System (Molecular Device) and acetylcholine (ACh) were added at its EC80. EC80 value was determined previously to the antagonist activity assay using the same batch of cells. Plates were mixed for 2 cycles and the fluorescence signal was read. Emission at 516 nm and measured fluorescence at 494 nm. Test compounds were tested in a 10-point 4-fold serial dilution with 100 nM - 10 pM as the maximum concentration. Apparent dissociation constant (KB) was calculated using GraphPad Prism 5 (GraphPad Software Inc., USA).Experiments were performed in duplicate.

[0231] In vitro human histamine H1 receptor (hH1) functional antagonism assay

[0232] Antagonism of human histamine H1 receptor was assessed using stable HEK293 cell lines expressing the hH1 receptor. Cells (2x104 / well) were added to the plates and incubated overnight at 37 °C and 5% CO2. Fluo-4 DirectTM (Life Technologies, Cat. # F10471), a fluorescent Ca2+indicator, was added at the final concentration of 4 pM. Test compounds were added to the plates and pre-incubated with cells for 1 hour (for 50 minutes at 37 °C and 5% CO2 and then for 10 min at room temperature). Afterwards, plates were transferred to FLIPR Tetra System (Molecular Device) and histamine was added at its EC80. EC80 value was determined previously to the antagonist activity assay using the same batch of cells. Plates were mixed for 2 cycles and the fluorescence signal was read. Emission at 516 nm and measured fluorescence at 494 nm. Test compounds were tested in a 10- point 3-fold serial dilution with 100 nM - 100 pM as the maximum concentration. Apparent dissociation constant (KB) were calculated using GraphPad Prism 5 (GraphPad Software Inc., USA). Experiments performed in duplicate.

[0233] [Table 2], In vitro pharmacology at human histamine H1 and muscarinic M3 receptors (binding affinity and functional antagonism)>>Data is shown as mean ± S.D. of n=2-7 independent experiments. KB - apparent dissociation constant. K - inhibition constant. Experiments were performed in duplicates. NT - not tested.Example 2 - Pharmacokinetic tests

[0234] The pharmacokinetic profile of Ipatropium bromide, Olopatadine, ACH- 001806, and ACH-001796 was evaluated following a single intranasal administration at a dose of 65 nmol / kg in male Sprague-Dawley rats (n = 9 per group). Olopatadine and Ipatropium bromide served as reference compounds. Plasma and nasal cavity mucosal tissue samples were collected at predetermined time points post-administration and analyzed using liquid chromatography coupled with tandem mass spectrometry (LC- MS / MS) to quantify compound concentrations and determine pharmacokinetic parameters.

[0235] The pharmacokinetic profile of ACH-001806, and ACH-001796 was evaluated following a single p.o. administration at a dose of 3mg / kg inC57BL / 6J Mouse (n = 2 per group). Plasma and feces samples were collected at predetermined time points post-administration and analyzed using liquid chromatography coupled with tandem mass spectrometry (LC- MS / MS) to quantify compound concentrations and determine pharmacokinetic parameters.

[0236] Tables 3 and 4 demonstrate the long residence in nasal tissue after intranasal delivery for ACH-001796 and ACH-001806 in comparison to olopatadine and ipratropium: Significant amounts of the drug candidates were seen in the nasal mucosa for up to 24 hours (Table 4), with low systemic bioavailability (Table 3). A larger concentration and longer residence time was seen for ACH-001796 and ACH-001806 compared to Opatadine and Ipratropium.

[0237] [Table 3]: Plasma concentration (ng / ml) - nasal PK (mean ± SD)

[0238] [Table 4]: Nasal cavity mucosal layer concentration (ng / g) (mean ± SD)

[0239] [Table 5]: Plasma concentration (ng / ml) - oral PK

[0240] Table 6 shows the gut-restricted exposure with low systemic bioavailability after oral administration of examples ACH-001796 and ACH- 1806 from the series. Local action across the small and large intestine, with approximately 75% of the molecules recovered in the feces after oral administration is shown in Table 6.

[0241] [Table 6]: Fecal excretionND = Not determined (Parameters not determined due to inadequately defined terminal elimination phase)

Claims

Claims

1. A COMPOUND characterized in that it comprises a general formula I:wherein,X is selected from nitrogen or C-H;n = is an integer number selected from 0, 1 , 2, 3 or 4;m = is an integer number selected from 0, 1 or 2;R is a racemate selected from C-alkyl linear or branched chain (Ci-020), 0- or A / / - / -alkyl linear or branched chain (C1-C20);Y is selected from nitrogen or C-H;Z is selected from CH2, C-alkyl linear or branched chain (C1-C20), / V-alkyl linear or branched chain (C1-C20), oxygen, sulfur, sulfoxide or sulfone.M is selected from CH2, nitrogen, oxygen, sulfur, sulfoxide or sulfone;L is selected from CH2, nitrogen, oxygen or sulfur;A is absent or selected from hydrogen, alkyl linear or branched chain (C1-C20);His is a selected moiety from:or a pharmaceutically acceptable salt thereof.

2. THE COMPOUND of claim 1 , characterized in that X is N; R is CH3;Z is SO2; M is 0; L is N; A is H and / or n is 4.

3. THE COMPOUND of claim 1 or 2, characterized in that the salt is a halogen salt.

4. THE COMPOUND of any one of claims 1 to 3, characterized in that R is optionally selected from (S)-stereoisomers.

5. THE COMPOUND of any one of claims 1 to 4, characterized in that the compound of formula I is selected from:• 3-(3-((5-((S)-1 -(4-cycloheptylpiperazin-1 -y l)ethy l)py ridi n-2- yl)sulfonyl)phenoxy)-N-(4-((((S)-2-hydroxy-3-(naphthalen-1- yloxy)propyl)amino)methyl)phenyl)propenamide• (S)-N-(4-(((2-(benzhydryloxy)ethyl)amino)methyl)phenyl)-3-(3-((5-( 1 -(4-cyclohepty lpiperazin-1 -yl)ethyl)pyridin-2-yl)sulfonyl)phenoxy)propenamide• (S)-N-(4-((4-(6-chloro-1 H-benzo[d]imidazole-2-carbonyl)piperazin-1 -yl)methyl)phenyl)-3-(3-((5-(1 -(4-cycloheptylpiperazin-1 -yl)ethyl)pyridin-2-yl)sulfonyl)phenoxy)propenamide• (S)-3-(3-((5-(1 -(4-cycloheptylpiperazin-1 -y l)ethy I )pyridi n-2-yl)sulfonyl)phenoxy)-N-(4-((4-(1-(2-ethoxyethyl)-1H-benzo[d]imidazol- 2-y l)-1 ,4-diazepan-1 -yl)methyl)phenyl)propenamide• (S)-3-(3-((5-(1 -(4-cycloheptylpiperazin-1 -yl)ethyl)pyridin-2-yl)sulfonyl)phenoxy)-N-(4-((4-((1 -(4-fluorobenzyl)-1 H-benzo[d]imidazol-2-yl)amino)piperidin-1-yl)methyl)phenyl)propenamide• (S)-3-(3-((4-(1 -(4-cycloheptylpiperazin-1 -yl)ethyl)phenyl)sulfonyl)phenoxy)-N-(4-((4-(1-(2-ethoxyethyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methyl)phenyl)propenamide • (S)-3-(3-((5-(1 -(4-cycloheptylpiperazin-1 -y l)ethy I )pyridi n-2-yl)sulfonyl)phenoxy)-N-(4-((4-(1-(2-ethoxyethyl)-1H-benzo[d]imidazol- 2-yl)piperidin-1-yl)methyl)phenyl)propenamide• N-(4-((((R)-2-(3-chlorophenyl)-2-hydroxyethyl)amino)methyl)phenyl)-3-(3-((5-((S)-1-(4-cycloheptylpiperazin-1-yl)ethyl)pyridin-2-yl)sulfonyl)phenoxy)propenamide• (S)-N-(4-((4-(benzhydryloxy)piperidin-1-yl)methyl)phenyl)-3-(3-((5-(1 -(4-cycloheptylpiperazin-1 -yl)ethyl)pyridin-2-yl)sulfonyl)phenoxy)propenamide• (S)-N-(4-(3-(4-(8-chloro-5,6-dihydro-11 H-benzo[5,6]cyclohepta[1 , 2-b]py ridi n-11 -y I idene)piperid in-1 -yl)propyl)phenyl)-3-(3-((5-(1 -(4-cycloheptylpiperazin-1 -yl)ethyl)pyridin-2-yl)sulfonyl)phenoxy)propenamide• (S)-N-(4-((4-(8-chloro-5,6-dihydro-11 H-benzo[5,6]cyclohepta[1 ,2-b]py rid i n-11 -y I idene)piperidin-1 -yl)methyl)phenyl)-3-(3-((5-(1 -(4-cycloheptylpiperazin-1-yl)ethyl)pyridin-2-yl)sulfonyl)phenoxy)propenamide.

6. A PROCESS FOR OBTAINING THE COMPOUND of general formula I of claim 1 characterized in that it comprises the steps of: a) reacting compounds of formulas II and III under basic condition to obtain a product comprising the formula IV:Formula II Formula III Formula IVb) if Z in Formula IV is sulfur, optionally react compound of formula IV with an oxidant prior to step c);c) react a compound of formula IV under reductant conditions, followed by protection reaction with the remaining alcohol residue, that form a product comprising the formula V:Formula Vd) react the compounds of formula V and VI under mild conditions, followed by deprotection group under acidic conditions to form a compound of Formula VII:Formula VIIe) react the compounds of formula VII and VIII under reductiveamination conditions to form a compound of Formula IX:Formula VIII Formula IXf) react the compound of formula IX under de-alkylation conditions to form a compound of Formula X:Formula Xg) react the compound of formula X and formula XI under basic conditions to form a compound of Formula XII:Formula XI Formula XIIh) react the compound of formula XII under strong oxidation conditions to form a compound of Formula XIII:i) react the compounds of formula XIII and formula XIV under mild condensation conditions to form a compound of Formula I:Formula XIV Formula Iwhereinn is an integer number selected from 0, 1 , 2, 3 or 4; m is an integer number selected from 0, 1 or 2;X is selected from nitrogen or C-H;Halo is selected from Halogen;R is a racemate selected from C-alkyl linear or branched chain (Ci- 020), 0- or NH-alkyl linear or branched chain (C1-C20); more preferably, R is selected from (S)-stereoisomers;Y is selected from nitrogen or C-H;Z is selected from C-alkyl linear or branched chain (C1-C20), N-alkyl linear or branched chain (C1-C20), oxygen, sulfur, sulfoxide or sulfone.ZH is selected from CH-alkyl linear or branched chain (C1-C20), NH- alkyl linear or branched chain (C1-C20), hydroxyl or thiol.G is selected from CH3, NH2, Oxygen-C alkyl linear or branched chain (C1-C10) and thio-alkyl linear or branched chain (C1-C10);MH is selected from CH3, NH2, hydroxyl and thiol;M is selected from CH2, nitrogen, oxygen, sulfur, sulfoxide or sulfone;L is selected from CH2, nitrogen, oxygen and sulfur;A is absent or selected from hydrogen, alkyl linear or branched chain (C1-C20);PG - is selected from any protecting group; preferably, PG is selected from acetyl, tosyl, silyl derivativesHis is a selected moiety from

7. THE PROCESS, according to claim 6, characterized in that optionally, a salt of compound of Formula I is obtained from the reaction of the compound of Formula I with an inorganic acid in the presence of an organic solvent.

8. THE PROCESS, according to claim 7, characterized in that the inorganic salt is selected from the group comprising HBr or HCI.

9. THE PROCESS, according to claim 7, characterized in that the organic solvent is an aprotic solvent selected from the group comprising 1,4-dioxane or acetonitrile.

10. THE PROCESS, according to claim 6, characterized in that optionally, the racemate derivative from compound of formula IX obtained from step e) can be separated via SFC-separation procedure before proceeding to step f), wherein the enantiomer (S) is preferably used.

11. THE PROCESS, according to claim 6, characterized in that the compound of formula XIV is optionally obtained by reacting compounds of formula XV and formula XVI under reductive amination condition:_ Formula XV Formula XVI wherein A, L, His and m are as defined in claim 4.

12. A PHARMACEUTICAL COMPOSITION characterized in that it comprises at least one compound of general Formula I or pharmaceutically acceptable salts thereof, as defined in claim 1, in a therapeutically effective amount and at least one pharmaceutically acceptable excipient.

13. THE PHARMACEUTICAL COMPOSITION, according to claim 12, characterized in that it is administered orally, intranasally or via inhalation.

14. THE PHARMACEUTICAL COMPOSITION, according to claim 12 or 9, characterized in that it is formulated as a liquid suspension, a nasal spray, or inhaler.

15. A PHARMACEUTICAL COMBINATION characterized in that it comprises:i) at least one compound of general Formula I, as defined in claim 1, or any pharmaceutically acceptable salts thereof; andii) one or more agents selected from the list comprising a non-steroidal glucocorticoid receptor agonist or corticoids.

16. A MEDICAMENT characterized in that it comprises a compound of general Formula I or a pharmaceutically acceptable salt thereof, as defined in claim 1 , for use in treating a disease, said disease being selected from the group comprising asthma, chronic obstructive pulmonary disease (COPD), rhinitis, irritable bowel syndrome (IBS), spastic colitis, histamine intolerance, functional dyspepsia,eosinophilic esophagitis, gastroesophageal reflux disease (GERD), food intolerance and food allergy, and dermatitis, such as atopic dermatitis and allergic urticaria.

17. THE MEDICAMENT, according to claim 16, characterized in that it is for use in treating a respiratory disease selected fromasthma, COPD or rhinitis.

18. THE MEDICAMENT, according to claim 16 or 17, characterized in that the medicament is for human or veterinary use.

19. AN USE of at least one compound of general Formula I or a pharmaceutically acceptable salt thereof, as defined in claim 1, characterized in that it is for the manufacture of a medicament for treating a disease selected from the group comprising asthma, chronic obstructive pulmonary disease (COPD), rhinitis, irritable bowel syndrome (IBS), spastic colitis, histamine intolerance, functional dyspepsia, eosinophilic esophagitis, gastroesophageal reflux disease (GERD), food intolerance and food allergy, and dermatitis, such as atopic dermatitis and allergic urticaria.

20. THE USE, according to claims 19, characterized in that the disease is a human or veterinary disease.

21. A METHOD OF TREATING a disease characterized in that it comprises the administration of a therapeutically effective amount of at least one compound of general Formula I or a pharmaceutically acceptable salt thereof, as defined in claim 1 , to a patient in need.

22. THE METHOD OF TREATMENT, according to claim 21 ,characterized in that the disease is selected from the group comprising asthma, chronic obstructive pulmonary disease (COPD), rhinitis, irritable bowel syndrome (IBS), spastic colitis, histamine intolerance, functional dyspepsia, eosinophilic esophagitis, gastroesophageal reflux disease (GERD), food intolerance and food allergy, and dermatitis, such as atopic dermatitis and allergic urticaria.

23. THE METHOD OF TREATMENT, according to claim 21 or 22, characterized in that the therapeutically effective amount of the compound of general Formula I is from 0.0001 to 10,000 mg, optionally from 0.001 to 5,000 mg.

24. THE METHOD OF TREATMENT, according to any one of claims 21 to 23, characterized in that the compound of formula I is administered orally, intranasally or via inhalation.

25. THE METHOD OF TREATMENT, according to claim 21 ,characterized in that the patient is a human or animal.